<SEC-DOCUMENT>0001558370-20-011405.txt : 20201007
<SEC-HEADER>0001558370-20-011405.hdr.sgml : 20201007
<ACCEPTANCE-DATETIME>20201007161540
ACCESSION NUMBER:		0001558370-20-011405
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20201007
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201007
DATE AS OF CHANGE:		20201007

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		201229268

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>glyc-20201007x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7556.35618 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 10/7/2020 8:15:24 PM -->
      <!-- iXBRL Library version: 1.0.7556.35625 -->
      <!-- iXBRL Service Job ID: 0f89db27-4ab7-4469-b4f8-92d19b18ff29 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:glyc="http://www.glycomimetics.com/20201007" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:EntityCentralIndexKey" id="Tc_VaH1S18Zvk69RuOsdAMHaA_2_1">0001253689</ix:nonNumeric><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:AmendmentFlag" id="Tc_Nrsf9Z3gwUeWA9ZUdsLcRA_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="glyc-20201007.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-top:9pt double #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a8ff4002_8156_48fa_877e_0f8644b6b8da"></a><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;">UNITED STATES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">FORM </b><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:DocumentType" id="Narr_bGNGby8nt0awN5IPUdGbXw"><b style="font-weight:bold;letter-spacing:-0.1pt;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Pursuant to Section 13 or 15(d) of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;">Date of Report (Date of earliest event reported):</b><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_BPuph74-R0O-QXyvg9jv0Q"><b style="font-size:9pt;font-weight:bold;">October 7, 2020</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:EntityRegistrantName" id="Narr_k5Oi93dxVka4qReMfg8bpg"><b style="font-weight:bold;letter-spacing:-0.1pt;">GlycoMimetics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Exact name of registrant as specified in its charter)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_e1f4de58_61bd_4709_b865_8049cd6378dd"></a><a id="Tc_sRn2CJpT5E20FakP--FbsQ_2_0"></a><a id="Tc_IBS82UaABUmGoMqCak0CwQ_2_2"></a><a id="Tc_mrukLB9WVUiwA8PZOuzy2A_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_8Sgbgx9kYEeR8dqntphOJw_1_0"><b style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:EntityFileNumber" id="Tc_McKk9gvPE0u5xwJ0LxqhQQ_1_2"><b style="font-size:9pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">001-36177</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:EntityTaxIdentificationNumber" id="Tc_yI4GQP3ao0KZ3IP6pI4LUw_1_4"><b style="font-size:9pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">06-1686563</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(State or other jurisdiction of</span> <span style="letter-spacing:-0.1pt;">incorporation)</span></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Commission File Number)</span></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(IRS Employer</span><br /><span style="letter-spacing:-0.1pt;">Identification No.)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:EntityAddressAddressLine1" id="Narr_RJqL-GmxE0W8Zh_OQZftxw"><b style="font-size:9pt;font-weight:bold;">9708 Medical Center Drive</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:EntityAddressCityOrTown" id="Narr_Xssuo2XcbEqZJTpQKlVPMQ"><b style="font-size:9pt;font-weight:bold;">Rockville</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:EntityAddressStateOrProvince" id="Narr_6X4QLop2OESb8XyHF8tdoA"><b style="font-size:9pt;font-weight:bold;">MD</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:EntityAddressPostalZipCode" id="Narr_zfnYCtnzvkq4ypyxpG-iYQ"><b style="font-size:9pt;font-weight:bold;">20850</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Address of principal executive offices, including zip code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:CityAreaCode" id="Narr_OV9wMjeis0yhAG13Vj6EtA"><b style="font-size:9pt;font-weight:bold;">240</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:LocalPhoneNumber" id="Narr_XWYKhygIWUqLaS16xA6Izw"><b style="font-size:9pt;font-weight:bold;">243-1201</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Former name or former address, if changed since last report)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_JCGoSHVsdEaGsWp39mgiMA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_AW1-GrfTy02lxB5ST7qDoQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_oxIht_zao0WAOWpm8rPeuQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_24NtY3E_lUK7grcuVUdaKA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;letter-spacing:0pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;letter-spacing:0pt;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_815aaab8_f3ad_460f_b7c2_43bd0f552b4c"></a><div style="margin-left:0pt;"><a id="Tc_JhVy9VQSNEiQZnJTI4sBSQ_1_0"></a><a id="Tc_xer_FyTj6kKsubP9HexQBQ_1_1"></a><a id="Tc_x1zt6BcVDUO0rcAc5l9nUg_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:97.58%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Title of each class</b></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:44.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:Security12bTitle" id="Tc_VwrFh8a89EavCOgzwYmtRg_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" name="dei:TradingSymbol" id="Tc_9hl3qBhNoEGLvnY3EbLXqg_2_1"><span style="font-size:9pt;">GLYC</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:44.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_JTm3HZES8E6uRfU97ncGLQ_2_2"><span style="font-size:9pt;">The Nasdaq Stock Market</span></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Ind&#237;cate by check mark whether the registrant is an emerging growth Company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;">Emerging Growth Company </span><ix:nonNumeric contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_m9qMVBR8TU68nMcH1iFtGA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:97.58%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> <span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-bottom:9pt double #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Courier New';line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_9b3fb018_c176_4020_af5a_398b335adc8d"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:81.18%;border:0;margin:30pt 9.41% 30pt 9.41%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 1.01  Entry into a Material Definitive Agreement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On&#160;October 7,&#160;2020, GlycoMimetics, Inc. (the &#8220;<span style="font-style:italic;font-weight:bold;">Company</span>&#8221;) entered into a Sales Agreement (the &#8220;<span style="font-style:italic;font-weight:bold;">Agreement</span>&#8221;) with Cowen and Company, LLC (&#8220;<span style="font-style:italic;font-weight:bold;">Cowen</span>&#8221;) under which&#160;the Company&#160;may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the &#8220;<span style="font-style:italic;font-weight:bold;">Common Stock</span>&#8221;), having an aggregate offering price of up to $100,000,000 after the date of the Agreement through Cowen as its sales agent.<span style="font-family:'Tms Rmn';"> </span>Also on October 7, 2020, the Company filed a prospectus supplement offering&#160;up to&#160;$100,000,000 of shares of its&#160;Common&#160;Stock in accordance with the Agreement, on the Company&#8217;s Registration Statement on Form S-3 (No. 333-231577).&#160;&#160;The Agreement replaces the prior Sales Agreement between the Company and Cowen, dated September 28, 2017 (the &#8220;<span style="font-style:italic;font-weight:bold;">Prior Agreement</span>&#8221;). The Company sold an aggregate of $34.6 million in shares of Common Stock under the Prior Agreement. As a result of the expiration of the Company&#8217;s Registration Statement on Form S-3 (No. 333-220697), the parties have completed their obligations under the Prior Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Tms Rmn';">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Cowen may sell the Common Stock under the Agreement by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act of 1933, as amended, including without limitation sales made by means of ordinary brokers&#8217; transactions on The Nasdaq Global Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. Cowen will use commercially reasonable efforts to sell the Common Stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay Cowen a commission&#160;equal to&#160;three percent (3.0%) of the gross sales proceeds of any Common Stock sold through Cowen under the Agreement, and also has provided Cowen with customary indemnification rights. In addition, the Company has agreed to reimburse certain legal expenses and fees by Cowen in connection with the offering up to a maximum of $50,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Tms Rmn';">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is not obligated to make any sales of Common Stock under the Agreement. The offering of shares of Common Stock pursuant to the Agreement will terminate upon the earlier of (i) the sale of all Common Stock subject to the Agreement or (ii) termination of the Agreement in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Tms Rmn';">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Tms Rmn';">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein, nor shall there be any offer, solicitation, or sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Tms Rmn';margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 9.01 &#160;Financial Statements and Exhibits. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(d)&#160;Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:96.29%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.37%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:90.34%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.37%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"></td><td style="vertical-align:top;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:90.34%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:8.37%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit</b></p></td><td style="vertical-align:top;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:90.34%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:8.37%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Number</b></p></td><td style="vertical-align:top;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:90.34%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.37;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit&#160;Description</b></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;text-indent:-7.2pt;margin:5pt 0pt 5pt 0pt;">1.1</p></td><td style="vertical-align:top;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:90.34%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:5pt 0pt 5pt 0pt;"><a style="-sec-extract:exhibit;" href="glyc-20201007xex1d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.37;text-align:justify;">Sales Agreement, dated October 7, 2020, by and between the Company and Cowen and Company, LLC.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;text-indent:-7.2pt;margin:5pt 0pt 5pt 0pt;">5.1</p></td><td style="vertical-align:top;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:5pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.34%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:5pt 0pt 5pt 0pt;"><a style="-sec-extract:exhibit;" href="glyc-20201007xex5d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.37;text-align:justify;">Opinion of Cooley LLP.</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;text-indent:-7.2pt;margin:5pt 0pt 5pt 0pt;">23.1</p></td><td style="vertical-align:top;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:5pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:90.34%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:5pt 0pt 5pt 0pt;">Consent of Cooley LLP (included in Exhibit 5.1).</p></td></tr><tr><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;text-indent:-7.2pt;margin:5pt 0pt 5pt 0pt;">104</p></td><td style="vertical-align:top;width:1.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:90.34%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:justify;margin:5pt 0pt 5pt 0pt;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.05pt;margin:0pt;"><span style="font-size:0.05pt;visibility:hidden;">&#8203;</span></p><a id="_46a103c6_3a69_4f46_8ee0_a528443059fa"></a></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;text-align:justify;text-indent:37.05pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.7pt;padding-right:0.7pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></div></div></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GLYCOMIMETICS, INC.</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="letter-spacing:-0.1pt;">By:&#160;&#160;</span></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">/s/ </span>Brian M. Hahn</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:-0.1pt;white-space:pre-wrap;">Date:  </span>October 7, 2020</p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian M. Hahn<br />Chief Financial Officer and Senior Vice President</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>glyc-20201007xex1d1.htm
<DESCRIPTION>EX-1.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 10/7/2020 08:15:14 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 1.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-size:12pt;font-weight:bold;">GLYCOMIMETICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><font style="font-size:12pt;">Common Stock</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">(par value $0.001 per share)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SALES AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 5pt 0pt;"><font style="font-size:12pt;">October 7, 2020</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Cowen and Company, LLC</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">599 Lexington Avenue</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">New York, NY 10022</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Ladies and Gentlemen:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">GlycoMimetics, Inc., a Delaware corporation (the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Company</b><font style="font-size:12pt;">&#8221;), confirms its agreement (this &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Agreement</b><font style="font-size:12pt;">&#8221;) with Cowen and Company, LLC (&#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Cowen</b><font style="font-size:12pt;">&#8221;), as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">1.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Issuance and Sale of Shares</u><font style="font-size:12pt;">. &#160;The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue and sell through Cowen, acting as agent and/or principal, shares (the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Placement Shares</b><font style="font-size:12pt;">&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Common Stock</b><font style="font-size:12pt;">&#8221;), having an aggregate offering price of up to $100,000,000. &#160;Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 1</u><font style="font-size:12pt;"> on the number of shares of Common Stock issued and sold under this Agreement shall be the sole responsibility of the Company, and Cowen shall have no obligation in connection with such compliance. &#160;The issuance and sale of Common Stock through Cowen will be effected pursuant to the Registration Statement (as defined below) filed, or to be filed, by the Company and after such Registration Statement has been declared effective by the Securities and Exchange Commission (the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Commission</b><font style="font-size:12pt;">&#8221;), although nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement (as defined below) to issue the Common Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Company has filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Securities Act</b><font style="font-size:12pt;">&#8221;), with the Commission a registration statement on Form S-3 (File No. 333-231577), which was declared effective on May 28, 2019, including a prospectus, relating to the Placement Shares, to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exchange Act</b><font style="font-size:12pt;">&#8221;). The Company will prepare and file a prospectus supplement specifically relating to the Placement Shares (the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Prospectus Supplement</b><font style="font-size:12pt;">&#8221;) to the prospectus specifically relating to the Placement Shares included as part of such registration statement. &#160;The Company has furnished to Cowen, for use by Cowen, copies of the prospectus included as part of such registration statement, as supplemented by a Prospectus Supplement, relating to the Placement Shares. &#160;Except where the context otherwise requires, such registration statement, and any post-effective amendment thereto, as amended when it becomes effective, including all documents</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B or 462(b) of the Securities Act, is herein called the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Registration Statement</b><font style="font-size:12pt;">.&#8221; The prospectus, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented by a Prospectus Supplement, in the form in which such prospectus and/or Prospectus Supplement have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any &#8220;issuer free writing prospectus,&#8221; as defined in Rule 433 of the Securities Act regulations (&#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Rule 433</b><font style="font-size:12pt;">&#8221;), relating to the Placement Shares that (i) is required to be filed with the Commission by the Company or (ii) is exempt from filing pursuant to Rule 433(d)(5)(i), in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&#8217;s records pursuant to Rule 433(g), is herein called the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Prospectus</b><font style="font-size:12pt;">.&#8221; Any reference herein to the Registration Statement, the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated by reference therein, and any reference herein to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof of any document with the Commission deemed to be incorporated by reference therein. For purposes of this Agreement, all references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include any copy filed with the Commission pursuant via the Electronic Data Gathering Analysis and Retrieval System (&#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EDGAR</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">2.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Placements</u><font style="font-size:12pt;">. &#160;Each time that the Company wishes to issue and sell the Placement Shares hereunder (each, a &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Placement</b><font style="font-size:12pt;">&#8221;), it will notify Cowen by email notice (or other method mutually agreed to in writing by the parties) (a &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Placement Notice</b><font style="font-size:12pt;">&#8221;) containing the parameters in accordance with which it desires the Placement Shares to be sold, which shall at a minimum include the number of Placement Shares to be issued, the time period during which sales are requested to be made, any limitation on the number of Placement Shares that may be sold in any one Trading Day (as defined in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 3</u><font style="font-size:12pt;">) and any minimum price below which sales may not be made, a form of which containing such minimum sales parameters necessary is attached hereto as </font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule 1</b><font style="font-size:12pt;">. &#160;The Placement Notice shall originate from any of the individuals from the Company set forth on </font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule 2</b><font style="font-size:12pt;"> (with a copy to each of the other individuals from the Company listed on such schedule), and shall be addressed to each of the individuals from Cowen set forth on </font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule 2</b><font style="font-size:12pt;">, as such </font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule 2</b><font style="font-size:12pt;"> may be amended from time to time. The Placement Notice shall be effective upon receipt by Cowen unless and until (i) in accordance with the notice requirements set forth in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 4</u><font style="font-size:12pt;">, Cowen declines to accept the terms contained therein for any reason, in its sole discretion, (ii) the entire amount of the Placement Shares have been sold, (iii) in accordance with the notice requirements set forth in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 4</u><font style="font-size:12pt;">, the Company suspends or terminates the Placement Notice for any reason, in its sole discretion, (iv) the Company issues a subsequent Placement Notice with parameters superseding those on the earlier dated Placement Notice, or (v) this Agreement has been terminated under the provisions of </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 11</u><font style="font-size:12pt;">. &#160; The amount of any discount, commission or other compensation to be paid by the Company to Cowen in connection with the sale of the Placement Shares shall be calculated in accordance with the terms set forth in </font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule 3</b><b style="font-size:12pt;font-weight:bold;">.</b><font style="font-size:12pt;"> &#160;It is expressly acknowledged and agreed that neither the Company nor Cowen will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to Cowen and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">2</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Cowen does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein and herein. &#160;In the event of a conflict between the terms of this Agreement and the terms of a Placement Notice, the terms of the Placement Notice will control.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">3.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Sale of Placement Shares by Cowen.</u><font style="font-size:12pt;"> &#160;Subject to the terms and conditions herein set forth, upon the Company&#8217;s delivery of a Placement Notice, and unless the sale of the Placement Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement, Cowen, for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Stock Market LLC (&#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Nasdaq</b><font style="font-size:12pt;">&#8221;) to sell such Placement Shares up to the amount specified, and otherwise in accordance with the terms of such Placement Notice. &#160;Cowen will provide written confirmation to the Company (including by email correspondence to each of the individuals of the Company set forth on </font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule 2</b><font style="font-size:12pt;">, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) no later than the opening of the Trading Day (as defined below) immediately following the Trading Day on which it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day, the volume-weighted average price of the Placement Shares, and the Net Proceeds (as defined below) payable to the Company. &#160;Cowen may sell Placement Shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act, including without limitation sales made through Nasdaq, on any other existing trading market for the Common Stock or to or through a market maker. &#160;If expressly authorized by the Company in a Placement Notice, Cowen may also sell Placement Shares in negotiated transactions. &#160;Notwithstanding the provisions of </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 6(jj)</u><font style="font-size:12pt;">, Cowen shall not purchase Placement Shares for its own account as principal unless expressly authorized to do so by the Company in a Placement Notice. &#160;The Company acknowledges and agrees that (i) there can be no assurance that Cowen will be successful in selling Placement Shares, and (ii) Cowen will incur no liability or obligation to the Company or any other person or entity if it does not sell Placement Shares for any reason other than a failure by Cowen to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such Placement Shares as required under this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 3</u><font style="font-size:12pt;">. &#160; For the purposes hereof, &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Trading Day</b><font style="font-size:12pt;">&#8221; means any day on which the Company&#8217;s Common Stock is purchased and sold on Nasdaq.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">4.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Suspension of Sales</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:12pt;">The Company or Cowen may, upon notice to the other party in writing (including by email correspondence to each of the individuals of the other party set forth on </font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule 2</b><font style="font-size:12pt;">, if receipt of such correspondence is actually acknowledged by any of the individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable facsimile transmission or email correspondence to each of the individuals of the other party set forth on </font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule 2</b><font style="font-size:12pt;">), suspend any sale of Placement Shares; </font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that such suspension shall not affect or impair either party&#8217;s obligations with respect to any Placement Shares sold hereunder prior to the receipt of such notice. &#160;Each of the parties agrees that no such notice under this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 4</u><font style="font-size:12pt;"> shall be effective against the other unless it is made to one of the individuals named on </font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Schedule 2</b><font style="font-size:12pt;"> hereto, as such schedule may be amended from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">3</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:12pt;">Notwithstanding any other provision of this Agreement, during any period in which the Company is in possession of material non-public information, the Company and Cowen agree that (i) no sale of Placement Shares will take place, (ii) the Company shall not request the sale of any Placement Shares, and (iii) Cowen shall not be obligated to sell or offer to sell any Placement Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:12pt;">If either Cowen or the Company has reason to believe that the exemptive provisions set forth in Rule 101(c)(1) of Regulation M under the Exchange Act are not satisfied with respect to the Common Stock, it shall promptly notify the other party, and Cowen may, at its sole discretion, suspend sales of the Placement Shares under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">5.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Settlement.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Settlement of Placement Shares</u><font style="font-size:12pt;">. &#160;Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares will occur on the second (2</font><sup style="font-size:9pt;vertical-align:top;">nd</sup><font style="font-size:12pt;">) Trading Day (or such earlier day as is industry practice for regular-way trading) following the date on which such sales are made (each, a &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Settlement Date</b><font style="font-size:12pt;">&#8221; and the first such settlement date, the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">First Delivery Date</b><font style="font-size:12pt;">&#8221;). &#160;The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of the Placement Shares sold (the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Net Proceeds</b><font style="font-size:12pt;">&#8221;) will be equal to the aggregate sales price received by Cowen at which such Placement Shares were sold, after deduction for (i)&#160;Cowen&#8217;s commission, discount or other compensation for such sales payable by the Company pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 2</u><font style="font-size:12pt;"> hereof, (ii) any other amounts due and payable by the Company to Cowen hereunder pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(g)</u><font style="font-size:12pt;"> hereof, and (iii) any transaction fees imposed by any governmental or self-regulatory organization in respect of such sales.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Delivery of Placement Shares</u><font style="font-size:12pt;">. &#160;On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer the Placement Shares being sold by crediting Cowen&#8217;s or its designee&#8217;s account (provided Cowen shall have given the Company written notice of such designee at least one Trading Day prior to the Settlement Date) at The Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may be mutually agreed upon by the parties hereto which in all cases shall be freely tradeable, transferable, registered shares in good deliverable form. &#160;On each Settlement Date, Cowen will deliver the related Net Proceeds in same day funds to an account designated by the Company on, or prior to, the Settlement Date. &#160;The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation to deliver duly authorized Placement Shares on a Settlement Date, the Company agrees that in addition to and in no way limiting the rights and obligations set forth in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9(a)</u><font style="font-size:12pt;"> hereto, it will (i)&#160;hold Cowen harmless against any loss, claim, damage, or reasonable and documented expense (including reasonable and documented legal fees and expenses), as incurred, arising out of or in connection with such default by the Company and (ii) pay to Cowen (without duplication) any commission, discount, or other compensation to which it would otherwise have been entitled absent such default.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">6.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Representations and Warranties of the Company</u><font style="font-size:12pt;">. &#160;Except as disclosed in the Registration Statement, the Prospectus or any Prospectus Supplement, the Company represents and warrants to, and agrees with, Cowen that, unless such representation, warranty or agreement specifies otherwise, as of the date of this Agreement, each Representation Date (as defined in</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">4</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Section 7(m)), each date on which a Placement Notice is given, and any date on which Placement Shares are sold hereunder:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Compliance with Registration Requirements</u><font style="font-size:12pt;">. The Registration Statement and any Rule&#160;462(b) Registration Statement have been declared effective by the Commission under the Securities Act. &#160;The Company has complied to the Commission&#8217;s satisfaction with all requests of the Commission for additional or supplemental information. &#160;No stop order suspending the effectiveness of the Registration Statement or any Rule&#160;462(b) Registration Statement is in effect and no proceedings for such purpose have been instituted or are pending or, to the best knowledge of the Company, contemplated or threatened by the Commission. &#160;The Company meets the requirements for use of Form S-3 under the Securities Act. &#160;The sale of the Placement Shares hereunder meets the requirements of General Instruction I.B.1 of Form S-3. &#160;Notwithstanding anything to the contrary contained in this Agreement, the representations and warranties set forth in the first three sentences of this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 6(a)</u><font style="font-size:12pt;"> shall not be made by the Company as of the date of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)&#160; </font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Misstatement or Omission</u><font style="font-size:12pt;">. &#160;The Prospectus when filed complied and, as amended or supplemented, if applicable, will comply in all material respects with the Securities Act. &#160;Each of the Registration Statement, any Rule&#160;462(b) Registration Statement, the Prospectus and any post-effective amendments or supplements thereto, at the time it became effective or its date, as applicable, complied, and as of each of the Settlement Dates, if any, complied in all material respects with the Securities Act and did not and, as of each Settlement Date, if any, did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. The Prospectus, as amended or supplemented, as of its date, did not and, as of each of the Settlement Dates, if any, will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The representations and warranties set forth in the two immediately preceding sentences do not apply to statements in or omissions from the Registration Statement, any Rule&#160;462(b) Registration Statement, or any post-effective amendment thereto, or the Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with information relating to Cowen furnished to the Company in writing by Cowen expressly for use therein. &#160;There are no contracts or other documents required to be described in the Prospectus or to be filed as exhibits to the Registration Statement which have not been described or filed as required. Notwithstanding anything to the contrary contained in this Agreement, the representations and warranties set forth in this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 6(b)</u><font style="font-size:12pt;"> shall not be made by the Company as of the date of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Offering Materials Furnished to Cowen</u><font style="font-size:12pt;">. The Company has delivered to Cowen one complete copy of the Registration Statement and a copy of each consent and certificate of experts filed as a part thereof, and conformed copies of the Registration Statement (without exhibits) and the Prospectus, as amended or supplemented, in such quantities and at such places as Cowen has reasonably requested.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Not an Ineligible Issuer</u><font style="font-size:12pt;">. The Company currently is not an &#8220;ineligible issuer,&#8221; as defined in Rule 405 of the rules and regulation of the Commission. &#160;The Company agrees to notify Cowen promptly upon the Company becoming an &#8220;ineligible issuer.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">5</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Distribution of Offering Material By the Company</u><font style="font-size:12pt;">. The Company has not distributed and will not distribute, prior to the completion of Cowen&#8217;s distribution of the Placement Shares pursuant to this Agreement, any offering material in connection with the offering and sale of the Placement Shares other than the Prospectus or the Registration Statement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">The Sales Agreement</u><font style="font-size:12pt;">. This Agreement has been duly authorized, executed and delivered by, and is a valid and binding agreement of, the Company, enforceable in accordance with its terms, except as rights to indemnification hereunder may be limited by applicable law and except as the enforcement hereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(g)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Authorization of the Placement Shares</u><font style="font-size:12pt;">. The Placement Shares, when issued and delivered, will be duly authorized for issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor pursuant to this Agreement, will be duly authorized, validly issued, fully paid and nonassessable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(h)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Applicable Registration or Other Similar Rights</u><font style="font-size:12pt;">. There are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, except for such rights as have been duly waived.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Material Adverse Change</u><font style="font-size:12pt;">. &#160;Except as otherwise disclosed in the Prospectus, subsequent to the respective dates as of which information is given in the Prospectus: (i)&#160;there has been no material adverse change, or any development that could reasonably be expected to result in a material adverse change, in the condition, financial or otherwise, or in the earnings, business, operations or prospects, whether or not arising from transactions in the ordinary course of business, of the Company (any such change is called a &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Material Adverse Change</b><font style="font-size:12pt;">&#8221;); (ii)&#160;the Company has not incurred any material liability or obligation, indirect, direct or contingent, not in the ordinary course of business nor entered into any material transaction or agreement not in the ordinary course of business; and (iii)&#160;there has been no dividend or distribution of any kind declared, paid or made by the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(j)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Independent Accountants</u><font style="font-size:12pt;">. &#160;Ernst &amp; Young LLP, who has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission or incorporated by reference as a part of the Registration Statement and included in the Prospectus, is an independent registered public accounting firm as required by the Securities Act and the Exchange Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(k)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Preparation of the Financial Statements</u><font style="font-size:12pt;">. The financial statements filed with the Commission as a part of or incorporated by reference in the Registration Statement and included in the Prospectus present fairly, in all material respects, the financial position of the Company as of and at the dates indicated and the results of their operations and cash flows for the periods specified. &#160;Such financial statements have been prepared in accordance with generally accepted accounting principles as applied in the United States applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. &#160;No other financial statements or supporting schedules are required to be included in or incorporated in the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">6</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Registration Statement. &#160;The financial data set forth or incorporated in the Prospectus under the captions &#8220;Ratio of Earnings to Combined Fixed Charges and Preferred Stock Dividends&#8221; and &#8220;Selected Financial Data&#8221; fairly present, in all material respects, the information set forth therein on a basis consistent with that of the audited financial statements contained, incorporated or deemed to be incorporated in the Registration Statement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(l)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">XBRL</u><font style="font-size:12pt;">. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the each Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(m)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Incorporation and Good Standing of the Company</u><font style="font-size:12pt;">. The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the State of Delaware and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in the Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good standing in the State of Maryland and each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except for such jurisdictions (other than the State of Maryland) where the failure to so qualify or to be in good standing would not, individually or in the aggregate, result in a Material Adverse Change. &#160;The Company does not own or control, directly or indirectly, any corporation, association or other entity other than any subsidiaries formed since the date of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(n)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Capital Stock Matters</u><font style="font-size:12pt;">. The Common Stock conforms in all material respects to the description thereof contained in the Prospectus. &#160;All of the issued and outstanding shares of Common Stock have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with federal and state securities laws. &#160;None of the outstanding shares of Common Stock were issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. &#160;There are no authorized or outstanding options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company other than those accurately described in all material respects in the Prospectus. &#160;The description of the Company&#8217;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set forth in the Prospectus accurately and fairly presents in all material respects the information required to be shown with respect to such plans, arrangements, options and rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(o)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Non-Contravention of Existing Instruments; No Further Authorizations or Approvals Required</u><font style="font-size:12pt;">. &#160; The Company is not in violation of its charter or by-laws or is in default (or, with the giving of notice or lapse of time, would be in default) (&#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Default</b><font style="font-size:12pt;">&#8221;) under any indenture, mortgage, loan or credit agreement, note, contract, franchise, lease or other instrument to which the Company is a party or by which it may be bound, or to which any of the property or assets of the Company is subject (each, an &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Existing Instrument</b><font style="font-size:12pt;">&#8221;), except for such Defaults as would not, individually or in the aggregate, result in a Material Adverse Change. &#160;The Company&#8217;s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by the Prospectus (i)&#160;have been duly authorized by all necessary corporate action and will not result in any violation of the provisions of the charter or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">7</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">by-laws of the Company, (ii)&#160;will not conflict with or constitute a breach of, or Default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant to, or require the consent of any other party to, any Existing Instrument, except for such conflicts, breaches, Defaults, liens, charges or encumbrances as would not, individually or in the aggregate, result in a Material Adverse Change, and (iii)&#160;will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company. &#160;No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the Company&#8217;s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act, applicable state securities or blue sky laws and from the Financial Industry Regulatory Authority (&#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">FINRA</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(p)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Material Actions or Proceedings</u><font style="font-size:12pt;">. &#160;Except as disclosed in the Prospectus, there are no legal or governmental actions, suits or proceedings pending or, to the best of the Company&#8217;s knowledge, threatened (i)&#160;against or affecting the Company, (ii)&#160;which has as the subject thereof any officer or director of, or property owned or leased by, the Company or (iii)&#160;relating to environmental or discrimination matters, where in any such case (A)&#160;there is a reasonable possibility that such action, suit or proceeding might be determined adversely to the Company and (B)&#160;any such action, suit or proceeding, if so determined adversely, would reasonably be expected to result in a Material Adverse Change or adversely affect the consummation of the transactions contemplated by this Agreement. &#160;No material labor dispute with the employees of the Company exists or, to the Company&#8217;s knowledge, is threatened or imminent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(q)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">All Necessary Permits, etc</u><font style="font-size:12pt;">. &#160;The Company possesses such valid and current certificates, authorizations or permits issued by the appropriate state, federal or foreign regulatory agencies or bodies (including, without limitation, those administered by the U.S. Food and Drug Administration (the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">FDA</b><font style="font-size:12pt;">&#8221;) or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA) necessary to conduct its business, other than those the failure to possess or own would not result in a Material Adverse Change, and the Company has not received any notice of proceedings relating to the revocation or modification of, or non-compliance with, any such certificate, authorization or permit which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, could result in a Material Adverse Change.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(r)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Tax Law Compliance</u><font style="font-size:12pt;">. &#160;The Company has filed all necessary federal, state and foreign income, property and franchise tax returns (or has properly requested extensions thereof) and has paid all taxes required to be paid by it and, if due and payable, any related or similar assessment, fine or penalty levied against it except as may be being contested in good faith and by appropriate proceedings. &#160;The Company has made adequate charges, accruals and reserves in the applicable financial statements referred to in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 6(k)</u><font style="font-size:12pt;"> above in respect of all federal, state and foreign income, property and franchise taxes for all periods as to which the tax liability of the Company has not been finally determined.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(s)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company Not an &#8220;Investment Company.</u><font style="font-size:12pt;">&#8221; The Company is not, and after receipt of payment for the Common Stock will not be, an &#8220;investment company&#8221; within the meaning of Investment Company Act of 1940, as amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">8</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(t)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Insurance</u><font style="font-size:12pt;">. &#160;Except as otherwise described in the Prospectus, the Company is insured by insurers of recognized financial responsibility with policies in such amounts and with such deductibles and covering such risks as are generally deemed prudent and customary for the business for which it is engaged. &#160;The Company has no reason to believe that it will not be able (i)&#160;to renew its existing insurance coverage as and when such policies expire or (ii)&#160;to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material Adverse Change.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(u)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Price Stabilization or Manipulation</u><font style="font-size:12pt;">. &#160;The Company has not taken and will not take, directly or indirectly, any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Placement Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(v)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Related Party Transactions</u><font style="font-size:12pt;">. &#160;There are no business relationships or related-party transactions involving the Company or any other person required to be described in the Prospectus which have not been described as required.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(w)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exchange Act Compliance</u><font style="font-size:12pt;">. &#160;The documents incorporated or deemed to be incorporated by reference in the Prospectus, at the time they were or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the Exchange Act, and, when read together with the other information in the Prospectus, at the Settlement Dates, will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(x)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Unlawful Contributions or Other Payments</u><font style="font-size:12pt;">. &#160;Neither the Company nor, to the best of the Company&#8217;s knowledge, any director, officer, employee or agent of the Company has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(y)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Compliance with Money Laundering Laws</u><font style="font-size:12pt;">. &#160;The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Money Laundering Laws</b><font style="font-size:12pt;">&#8221;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(z)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Compliance with OFAC</u><font style="font-size:12pt;">. &#160;Neither the Company nor, to the knowledge of the Company, any director, officer, agent, employee or affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">OFAC</b><font style="font-size:12pt;">&#8221;); and the Company will not, directly or indirectly, use the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">9</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">proceeds of the offering of the Placement Shares hereunder, or lend, contribute or otherwise make available such proceeds to any joint venture partner or other person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(aa)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company&#8217;s Accounting System</u><font style="font-size:12pt;">. &#160;The Company maintains a system of &#8220;internal control over financial reporting&#8221; (as such term is defined in Rule 13a-15(f) of the General Rules and Regulations under the Exchange Act (the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exchange Act Rules</b><font style="font-size:12pt;">&#8221;)) that complies with the requirements of the Exchange Act and has been designed by their respective principal executive and principal financial officers, or under their supervision, to provide reasonable assurances that (i) transactions are executed in accordance with management&#8217;s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with U.S. GAAP and to maintain accountability for assets; (iii) access to assets is permitted only in accordance with management&#8217;s general or specific authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences. &#160;The Company&#8217;s system of internal control over financial reporting is effective in all material respects to perform the functions for which it was established. &#160;Except as described in the Prospectus, since the end of the Company&#8217;s most recent audited fiscal year, there has been (A) no material weakness in the Company&#8217;s internal control over financial reporting (whether or not remediated) and (B) no change in the Company&#8217;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(bb)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Disclosure Controls</u><font style="font-size:12pt;">. The Company maintains disclosure controls and procedures (as such is defined in Rule 13a-15(e) of the Exchange Act Rules) that comply with the requirements of the Exchange Act; such disclosure controls and procedures have been designed to ensure that information required to be disclosed by the Company in reports that it files or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#8217;s management to allow timely decisions regarding disclosures. &#160;The Company has conducted evaluations of the effectiveness of their disclosure controls as required by Rule 13a-15 of the Exchange Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(cc)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Regulatory Matters</u><font style="font-size:12pt;">. The studies, tests and preclinical or clinical trials conducted by or on behalf of the Company that are described in the Prospectus (the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Company Studies and Trials</b><font style="font-size:12pt;">&#8221;) were and, if still pending, are being, conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional scientific standards; the descriptions of the results of the Company Studies and Trials contained in the Prospectus are accurate in all material respects; the Company has no knowledge of any other studies or trials not described in the Prospectus, the results of which are inconsistent with or call into question the results described or referred to in the Prospectus; and the Company has not received any notices or correspondence with the FDA or any foreign, state or local governmental body exercising comparable authority requiring the termination, suspension or material modification of any Company Studies or Trials that termination, suspension or material modification would reasonably be expected to have a Material Adverse Change and, to the Company&#8217;s knowledge, there are no reasonable grounds for the same. The</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">10</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Company has obtained informed consent by or on behalf of each human subject who participated in the Company Studies and Trials. In using or disclosing patient information received by the Company in connection with the Company Studies and Trials, the Company has complied in all material respects with all applicable laws and regulatory rules or requirements, including, without limitation, the Health Insurance Portability and Accountability Act of 1996 and the rules and regulations thereunder. To the Company&#8217;s knowledge, none of the Company Studies and Trials involved any investigator who has been disqualified as a clinical investigator or has been found by the FDA to have engaged in scientific misconduct. To the Company&#8217;s knowledge, the manufacturing facilities and operations of its suppliers are operated in compliance in all material respects with all applicable statutes, rules, regulations and policies of the FDA and comparable regulatory agencies outside of the United States to which the Company is subject, to the extent such parties are subject to the statures, rules regulation and policies of the FDA or comparable regulatory agency outside of the United States.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(dd)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Compliance with Environmental Laws</u><font style="font-size:12pt;">. Except as otherwise described in the Prospectus, and except as would not, individually or in the aggregate, result in a Material Adverse Change (i)&#160;the Company is not in violation of any federal, state, local or foreign law or regulation relating to pollution or protection of human health or the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including without limitation, laws and regulations relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum and petroleum products (collectively, &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Materials of Environmental Concern</b><font style="font-size:12pt;">&#8221;), or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Materials of Environmental Concern (collectively, &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Environmental Laws</b><font style="font-size:12pt;">&#8221;), which violation includes, but is not limited to, noncompliance with any permits or other governmental authorizations required for the operation of the business of the Company under applicable Environmental Laws, or noncompliance with the terms and conditions thereof, nor has the Company received any written communication, whether from a governmental authority, citizens group, employee or otherwise, that alleges that the Company is in violation of any Environmental Law; (ii)&#160;there is no claim, action or cause of action filed with a court or governmental authority, no investigation with respect to which the Company has received written notice, and no written notice by any person or entity alleging potential liability for investigatory costs, cleanup costs, governmental responses costs, natural resources damages, property damages, personal injuries, attorneys&#8217; fees or penalties arising out of, based on or resulting from the presence, or release into the environment, of any Material of Environmental Concern at any location owned, leased or operated by the Company, now or in the past (collectively, &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Environmental Claims</b><font style="font-size:12pt;">&#8221;), pending or, to the Company&#8217;s knowledge, threatened against the Company or any person or entity whose liability for any Environmental Claim the Company has retained or assumed either contractually or by operation of law; and (iii)&#160;to the best of the Company&#8217;s knowledge, there are no past or present actions, activities, circumstances, conditions, events or incidents, including, without limitation, the release, emission, discharge, presence or disposal of any Material of Environmental Concern, that reasonably could result in a violation of any Environmental Law or form the basis of a potential Environmental Claim against the Company or against any person or entity whose liability for any Environmental Claim the Company has retained or assumed either contractually or by operation of law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">11</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(ee)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Intellectual Property</u><font style="font-size:12pt;">. &#160;The Company owns or possesses the valid right to use all (i) patents, patent applications, trademarks, trademark registrations, service marks, service mark registrations, Internet domain name registrations, copyrights, copyright registrations, licenses, trade secret rights (&#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Intellectual Property Rights</b><font style="font-size:12pt;">&#8221;) and (ii) inventions, software, works of authorships, trademarks, service marks, trade names, databases, formulae, know how, Internet domain names and other intellectual property (including trade secrets and other unpatented and/or unpatentable proprietary confidential information, systems, or procedures) (collectively, &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Intellectual Property Assets</b><font style="font-size:12pt;">&#8221;) necessary to conduct its business as currently conducted, and as proposed to be conducted and described in the Prospectus. &#160;The Company has not received any opinion from their legal counsel concluding that any activities of its business infringes, misappropriates, or otherwise violates, valid and enforceable Intellectual Property Rights of any other person, and have not received written notice of any challenge, which is to its knowledge still pending, by any other person to the rights of the Company with respect to any Intellectual Property Rights or Intellectual Property Assets owned or used by the Company. &#160;To the knowledge of the Company, the Company&#8217;s &#160;business as now conducted does not give rise to any infringement of, any misappropriation of, or other violation of, any valid and enforceable Intellectual Property Rights of any other person. &#160;All licenses for the use of the Intellectual Property Rights described in the Prospectus are valid, binding upon, and enforceable by or against the parties thereto in accordance to its terms. &#160;The Company has complied in all material respects with, and is not in breach nor has received any asserted or threatened claim of breach of any Intellectual Property license, and the Company has no knowledge of any breach or anticipated breach by any other person to any Intellectual Property license. &#160;Except as described in the Prospectus, no claim has been made against the Company alleging the infringement by the Company of any patent, trademark, service mark, trade name, copyright, trade secret, license in or other intellectual property right or franchise right of any person. &#160;The Company has taken all reasonable steps to protect, maintain and safeguard its Intellectual Property Rights, including the execution of appropriate nondisclosure and confidentiality agreements. &#160;The consummation of the transactions contemplated by this Agreement will not result in the loss or impairment of or payment of any additional amounts with respect to, nor require the consent of any other person in respect of, the Company&#39;s right to own, use, or hold for use any of the Intellectual Property Rights as owned, used or held for use in the conduct of the business as currently conducted.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(ff)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Listing</u><font style="font-size:12pt;">. &#160;The Company is subject to and in compliance in all material respects with the reporting requirements of Section 13 or Section 15(d) of the Exchange Act. &#160;The shares of Common Stock are registered pursuant to Section 12(b) of the Exchange Act and are listed on Nasdaq, and the Company has taken no action designed to, or reasonably likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from Nasdaq, nor has the Company received any notification that the Commission or Nasdaq is contemplating terminating such registration or listing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(gg)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Brokers</u><font style="font-size:12pt;">. &#160;Except for Cowen, there is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder&#8217;s fee or other fee or commission as a result of any transactions contemplated by this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(hh)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Outstanding Loans or Other Indebtedness</u><font style="font-size:12pt;">. &#160;Except as described in the Prospectus, there are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees or indebtedness by the Company to or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">12</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">for the benefit of any of the officers or directors of the Company or any of the immediate family members of any of them.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Reliance</u><font style="font-size:12pt;">. &#160;The Company has not relied upon Cowen or legal counsel for Cowen for any legal, tax or accounting advice in connection with the offering and sale of the Placement Shares.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(jj)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Cowen Purchases</u><font style="font-size:12pt;">. &#160;The Company acknowledges and agrees that Cowen has informed the Company that Cowen may, to the extent permitted under the Securities Act and the Exchange Act, purchase and sell shares of Common Stock for its own account while this Agreement is in effect, </font><i style="font-size:12pt;font-style:italic;">provided, that</i><font style="font-size:12pt;"> (i) no such purchase or sales shall take place while a Placement Notice is in effect (except to the extent Cowen may engage in sales of Placement Shares purchased or deemed purchased from the Company as a &#8220;riskless principal&#8221; or in a similar capacity) and (ii) the Company shall not be deemed to have authorized or consented to any such purchases or sales by Cowen.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(kk)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Compliance with Laws</u><font style="font-size:12pt;">. &#160;The Company has not been advised, and has no reason to believe, that it is not conducting business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting business, except where failure to be so in compliance would not reasonably be expected to result in a Material Adverse Change.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Any certificate signed by an officer of the Company and delivered to Cowen or to counsel for Cowen in connection with this Agreement shall be deemed to be a representation and warranty by the Company to Cowen as to the matters set forth therein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">The Company acknowledges that Cowen and, for purposes of the opinions to be delivered pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7</u><font style="font-size:12pt;"> hereof, counsel to the Company and counsel to Cowen, will rely upon the accuracy and truthfulness of the foregoing representations and hereby consents to such reliance.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">7.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Covenants of the Company</u><font style="font-size:12pt;">. &#160;The Company covenants and agrees with Cowen that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Registration Statement Amendments</u><font style="font-size:12pt;">. &#160;After the date of this Agreement and during any period in which a Prospectus relating to any Placement Shares is required to be delivered by Cowen under the Securities Act (including in circumstances where such requirement may be satisfied pursuant to Rule&#160;172 under the Securities Act), (i)&#160;the Company will notify Cowen promptly of the time when any subsequent amendment to the Registration Statement, other than documents incorporated by reference, has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus has been filed and of any request by the Commission for any amendment or supplement to the Registration Statement or Prospectus or for additional information (insofar as it relates to the transactions contemplated hereby); (ii) the Company will prepare and file with the Commission, promptly upon Cowen&#8217;s request, any amendments or supplements to the Registration Statement or Prospectus that, in Cowen&#8217;s reasonable opinion, may be necessary or advisable in connection with the distribution of the Placement Shares by Cowen (</font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that the failure of Cowen to make such request shall not relieve the Company of any obligation or liability hereunder, or affect Cowen&#8217;s right to rely on the representations and warranties made by the Company in this Agreement and </font><i style="font-size:12pt;font-style:italic;">provided, further,</i><font style="font-size:12pt;"> that the only remedy Cowen shall have with respect to the failure to make such</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">13</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">filing will be to cease making sales under this Agreement until such amendment or supplement is filed); (iii) the Company will not file any amendment or supplement to the Registration Statement or Prospectus, other than documents incorporated by reference, relating to the Placement Shares or a security convertible into the Placement Shares unless a copy thereof has been submitted to Cowen within a reasonable period of time before the filing and Cowen has not reasonably objected thereto (</font><i style="font-size:12pt;font-style:italic;">provided, however</i><font style="font-size:12pt;">, that the failure of Cowen to make such objection shall not relieve the Company of any obligation or liability hereunder, or affect Cowen&#8217;s right to rely on the representations and warranties made by the Company in this Agreement and </font><i style="font-size:12pt;font-style:italic;">provided, further,</i><font style="font-size:12pt;"> that the only remedy Cowen shall have with respect to the failure to make such filing will be to cease making sales under this Agreement) and the Company will furnish to Cowen at the time of filing thereof a copy of any document that upon filing is deemed to be incorporated by reference into the Registration Statement or Prospectus, except for those documents available via EDGAR; and (iv) the Company will cause each amendment or supplement to the Prospectus, other than documents incorporated by reference, to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notice of Commission Stop Orders</u><font style="font-size:12pt;">. &#160;The Company will advise Cowen, promptly after it receives notice or obtains knowledge thereof, of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement, of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation or threatening of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain its withdrawal if such a stop order should be issued.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Delivery of Prospectus; Subsequent Changes</u><font style="font-size:12pt;">. &#160;During any period in which a Prospectus relating to the Placement Shares is required to be delivered by Cowen under the Securities Act with respect to a pending sale of the Placement Shares, (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act), the Company will use its commercially reasonable efforts to comply with all requirements imposed upon it by the Securities Act, as from time to time in force, and to file on or before their respective due dates (taking into account any extensions available under the Exchange Act) all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any other provision of or under the Exchange Act. &#160;If during such period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during such period it is necessary to amend or supplement the Registration Statement or Prospectus to comply with the Securities Act, the Company will promptly notify Cowen to suspend the offering of Placement Shares during such period and the Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission or effect such compliance; </font><i style="font-size:12pt;font-style:italic;">provided, however,</i><font style="font-size:12pt;"> that the Company may delay the filing of any amendment or supplement, if in the judgment of the Company, it is in the best interest of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">14</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Listing of Placement Shares</u><font style="font-size:12pt;">. &#160;During any period in which the Prospectus relating to the Placement Shares is required to be delivered by Cowen under the Securities Act with respect to a pending sale of the Placement Shares (including in circumstances where such requirement may be satisfied pursuant to Rule 172 under the Securities Act), the Company will use its commercially reasonable efforts to cause the Placement Shares to be listed on Nasdaq and to qualify the Placement Shares for sale under the securities laws of such jurisdictions as Cowen reasonably designates and to continue such qualifications in effect so long as required for the distribution of the Placement Shares; </font><i style="font-size:12pt;font-style:italic;">provided, however,</i><font style="font-size:12pt;"> that the Company shall not be required in connection therewith to qualify as a foreign corporation or dealer in securities or file a general consent to service of process in any jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Delivery of Registration Statement and Prospectus</u><font style="font-size:12pt;">. &#160;The Company will furnish to Cowen and its counsel (at the expense of the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein) and all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during any period in which a Prospectus relating to the Placement Shares is required to be delivered under the Securities Act (including all documents filed with the Commission during such period that are deemed to be incorporated by reference therein), in each case as soon as reasonably practicable and in such quantities as Cowen may from time to time reasonably request and, at Cowen&#8217;s request, will also furnish copies of the Prospectus to each exchange or market on which sales of the Placement Shares may be made; </font><i style="font-size:12pt;font-style:italic;">provided, however,</i><font style="font-size:12pt;"> that the Company shall not be required to furnish any document (other than the Prospectus) to Cowen or its counsel to the extent such document is available on EDGAR.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Earnings Statement</u><font style="font-size:12pt;">. &#160;The Company will make generally available to its security holders as soon as practicable, but in any event not later than 15 months after the end of the Company&#8217;s current fiscal quarter, an earnings statement covering a 12-month period that satisfies the provisions of Section 11(a) and Rule 158 of the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(g)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Expenses</u><font style="font-size:12pt;">. &#160;The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, in accordance with the provisions of </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 11</u><font style="font-size:12pt;"> hereunder, will pay the following expenses all incident to the performance of its obligations hereunder, including, but not limited to, expenses relating to (i) the preparation, printing and filing of the Registration Statement and each amendment and supplement thereto, of each Prospectus and of each amendment and supplement thereto, (ii) the preparation, issuance and delivery of the Placement Shares, (iii) the qualification of the Placement Shares under securities laws in accordance with the provisions of </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(d)</u><font style="font-size:12pt;"> of this Agreement, including filing fees (provided, however, that any fees or disbursements of counsel for Cowen in connection therewith shall be paid by Cowen except as set forth in (vii) below), (iv) the printing and delivery to Cowen of copies of the Prospectus and any amendments or supplements thereto, and of this Agreement, (v) the fees and expenses incurred in connection with the listing or qualification of the Placement Shares for trading on Nasdaq, (vi) the filing fees and expenses, if any, of the Commission and the filing fees and reasonable associated legal expenses of Cowen&#8217;s outside counsel for filings with the FINRA Corporate Financing Department, such legal expense reimbursement not to exceed $12,500, and (viii) the reasonable fees and disbursements of Cowen&#8217;s counsel in an amount not to exceed $50,000.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">15</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(h)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Use of Proceeds</u><font style="font-size:12pt;">. &#160;The Company will use the Net Proceeds as described in the Prospectus in the section entitled &#8220;Use of Proceeds.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notice of Other Sales</u><font style="font-size:12pt;">. &#160;During the pendency of any Placement Notice given hereunder, and for three trading days following the termination of any Placement Notice given hereunder, the Company shall provide Cowen notice as promptly as reasonably possible before it offers to sell, contracts to sell, sells, grants any option to sell or otherwise disposes of any shares of Common Stock (other than Placement Shares offered pursuant to the provisions of this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire Common Stock; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, that such notice shall not be required in connection with the (i) issuance, grant or sale of Common Stock, options or warrants to purchase shares of Common Stock, restricted shares of Common Stock, restricted stock units or other equity awards, or Common Stock issuable upon the exercise of options or other equity awards pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Prospectus, (ii) the issuance of securities in connection with an acquisition, merger or sale or purchase of assets, (iii) the issuance or sale of Common Stock pursuant to any dividend reinvestment plan that the Company may adopt from time to time provided the implementation of such is disclosed to Cowen in advance, (iv) any shares of Common Stock issuable upon the exchange, conversion or redemption of securities or the exercise of warrants, options or other rights in effect or outstanding or (v) the issuance or sale of Common Stock, or securities convertible into or exercisable for Common Stock, offered and sold in a privately negotiated transaction to vendors, customers, strategic partners or potential strategic partners conducted in a manner so as not to be integrated with the offering of Common Stock hereby. &#160;Notwithstanding the foregoing provisions, nothing herein shall be construed to restrict the Company&#8217;s ability, or require the Company to provide notice to Cowen, to file a registration statement under the Securities Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(j)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Change of Circumstances</u><font style="font-size:12pt;">. &#160;The Company will, at any time during a fiscal quarter in which the Company intends to tender a Placement Notice or sell Placement Shares, advise Cowen promptly after it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material respect any opinion, certificate, letter or other document provided to Cowen pursuant to this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(k)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Due Diligence Cooperation</u><font style="font-size:12pt;">. &#160;During the term of this Agreement, the Company will cooperate with any reasonable due diligence review conducted by Cowen or its agents in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents and senior corporate officers, during regular business hours and at the Company&#8217;s principal offices, as Cowen may reasonably request.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(l)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Required Filings Relating to Placement of Placement Shares</u><font style="font-size:12pt;">. &#160;The Company agrees that on such dates as the Securities Act shall require, the Company will (i)&#160;file a prospectus supplement with the Commission under the applicable paragraph of Rule 424(b) under the Securities Act (each and every filing under Rule 424(b), a &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Filing Date</b><font style="font-size:12pt;">&#8221;), which prospectus supplement will set forth, within the relevant period, the amount of Placement Shares sold through Cowen, the Net Proceeds to the Company and the compensation payable by the Company to Cowen with respect to such Placement Shares, and (ii) deliver such number of copies of each such prospectus supplement to each exchange or market on which such sales were effected as may be required by the rules or regulations of such exchange or market.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">16</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(m)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Representation Dates; Certificate</u><font style="font-size:12pt;">. &#160;On or prior to the First Delivery Date and thereafter, during the term of this Agreement, each time the Company (i) files the Prospectus relating to the Placement Shares or amends or supplements the Registration Statement or the Prospectus relating to the Placement Shares (other than a prospectus supplement filed in accordance with Section 7(l) of this Agreement) by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of document(s) by reference to the Registration Statement or the Prospectus relating to the Placement Shares; (ii) files an annual report on Form 10-K under the Exchange Act; (iii) files its quarterly reports on Form 10-Q under the Exchange Act; or (iv) files a report on Form 8-K containing amended financial information (other than information &#8220;furnished&#8221; pursuant to Items 2.02 or 7.01 of Form 8-K) under the Exchange Act (each date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Representation Date</b><font style="font-size:12pt;">&#8221;); the Company shall furnish Cowen with a certificate, in the form attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit 7(m)</u><font style="font-size:12pt;"> within two (2) Trading Days of any Representation Date if requested by Cowen. &#160;The requirement to provide a certificate under this Section 7(m) shall be automatically waived for any Representation Date occurring at a time at which no Placement Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Placement Notice hereunder (which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that such waiver shall not apply for any Representation Date on which the Company files its annual report on Form 10-K. &#160;Notwithstanding the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date when the Company relied on such waiver and did not provide Cowen with a certificate under this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(m)</u><font style="font-size:12pt;">, then before the Company delivers the Placement Notice or Cowen sells any Placement Shares, the Company shall provide Cowen with a certificate, in the form attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit 7(m)</u><font style="font-size:12pt;">, dated the date of the Placement Notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(n)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Legal Opinion</u><font style="font-size:12pt;">. &#160;On or prior to the First Delivery Date and within three (3) Trading Days of each Representation Date with respect to which the Company is obligated to deliver a certificate in the form attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit 7(m)</u><font style="font-size:12pt;"> for which no waiver is applicable, the Company shall cause to be furnished to Cowen a written opinion of Cooley LLP (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company Counsel</u><font style="font-size:12pt;">&#8221;), or other counsel satisfactory to Cowen, in form and substance satisfactory to Cowen and its counsel, dated the date that the opinion is required to be delivered, respectively, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that in lieu of such opinions for subsequent Representation Dates, Company Counsel may furnish Cowen with a letter (a &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Reliance Letter</b><font style="font-size:12pt;">&#8221;) to the effect that Cowen may rely on a prior opinion delivered under this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(n)</u><font style="font-size:12pt;"> to the same extent as if it were dated the date of such letter (except that statements in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(o)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Comfort Letter</u><font style="font-size:12pt;">. &#160;On or prior to the First Delivery Date and within three (3) Trading Days of each Representation Date with respect to which the Company is obligated to deliver a certificate in the form attached hereto as </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit 7(m)</u><font style="font-size:12pt;"> for which no waiver is applicable, the Company shall cause its independent accountants to furnish Cowen letters (the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Comfort Letters</b><font style="font-size:12pt;">&#8221;), dated the date the Comfort Letter is delivered, in form and substance satisfactory to Cowen, (i) confirming that they are an independent registered public accounting firm within the meaning of the Securities Act and the PCAOB, (ii) stating, as of such date, the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">17</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">conclusions and findings of such firm with respect to the financial information and other matters ordinarily covered by accountants&#8217; &#8220;comfort letters&#8221; to Cowen in connection with registered public offerings (the first such letter, the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Initial Comfort Letter</b><font style="font-size:12pt;">&#8221;) and (iii) updating the Initial Comfort Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date and modified as necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(p)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Market Activities</u><font style="font-size:12pt;">. &#160;The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Placement Shares or (ii) sell, bid for, or purchase the Common Stock to be issued and sold pursuant to this Agreement, or pay anyone any compensation for soliciting purchases of the Placement Shares other than Cowen; </font><i style="font-size:12pt;font-style:italic;">provided, however,</i><font style="font-size:12pt;"> that the Company may bid for and purchase shares of its Common Stock in accordance with Rule 10b-18 under the Exchange Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(q)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Insurance</u><font style="font-size:12pt;">. &#160;The Company shall maintain insurance in such amounts and covering such risks as is reasonable and customary for the business for which it is engaged.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(r)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Compliance with Laws</u><font style="font-size:12pt;">. &#160;The Company will use commercially reasonable efforts to maintain all material environmental permits, licenses and other authorizations required by federal, state and local law in order to conduct its business as described in the Prospectus, and the Company shall conduct its business, or cause its business to be conducted, in substantial compliance with such permits, licenses and authorizations and with applicable environmental laws, except where the failure to maintain or be in compliance with such permits, licenses and authorizations could not reasonably be expected to result in a Material Adverse Change.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(s)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Investment Company Act</u><font style="font-size:12pt;">. &#160;The Company will conduct its affairs in such a manner so as to reasonably ensure that it will not be or become, at any time prior to the termination of this Agreement, an &#8220;investment company,&#8221; as such term is defined in the Investment Company Act, assuming no change in the Commission&#8217;s current interpretation as to entities that are not considered an investment company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(t)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Securities Act and Exchange Act</u><font style="font-size:12pt;">. &#160;The Company will use its best efforts to comply with all requirements imposed upon it by the Securities Act and the Exchange Act as from time to time in force, so far as necessary to permit the continuance of sales of, or dealings in, the Placement Shares as contemplated by the provisions hereof and the Prospectus.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(u)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Offer to Sell</u><font style="font-size:12pt;">. &#160;Other than the Prospectus or a free writing prospectus (as defined in Rule 405 under the Securities Act) approved in advance by the Company and Cowen in its capacity as principal or agent hereunder, neither Cowen nor the Company (including its agents and representatives, other than Cowen in its capacity as such) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule 405 under the Securities Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer to buy Common Stock hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(v)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Sarbanes-Oxley Act</u><font style="font-size:12pt;">. &#160;The Company will use its best efforts to comply with all effective applicable provisions of the Sarbanes-Oxley Act.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">18</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">8.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Conditions to Cowen&#8217;s Obligations</u><font style="font-size:12pt;">. The obligations of Cowen hereunder with respect to a Placement will be subject to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance by the Company of its obligations hereunder, to the completion by Cowen of a due diligence review satisfactory to Cowen in its reasonable judgment, and to the continuing satisfaction (or waiver by Cowen in its sole discretion) of the following additional conditions:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Registration Statement Effective</u><font style="font-size:12pt;">. &#160;The Registration Statement shall be effective and shall be available for the sale of all Placement Shares contemplated to be issued by any Placement Notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Material Notices</u><font style="font-size:12pt;">. &#160;None of the following events shall have occurred and be continuing: &#160;(i) receipt by the Company of any request for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness of the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration Statement or the Prospectus; (ii)&#160;the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv) the occurrence of any event that makes any material statement made in the Registration Statement or the Prospectus or any material document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration Statement, related Prospectus or such documents so that, in the case of the Registration Statement, it will not contain any materially untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading and, that in the case of the Prospectus, it will not contain any materially untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Misstatement or Material Omission</u><font style="font-size:12pt;">. &#160;Cowen shall not have advised the Company that the Registration Statement or Prospectus, or any amendment or supplement thereto, contains an untrue statement of fact that in Cowen&#8217;s reasonable opinion is material, or omits to state a fact that in Cowen&#8217;s reasonable opinion is material and is required to be stated therein or is necessary to make the statements therein not misleading.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Material Changes</u><font style="font-size:12pt;">. &#160;Except as contemplated in the Prospectus, or disclosed in the Company&#8217;s reports filed with the Commission, there shall not have been any Material Adverse Change or any development that could reasonably be expected to result in a Material Adverse Change.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company Counsel Legal Opinion</u><font style="font-size:12pt;">. &#160;Cowen shall have received an opinion of Company Counsel required to be delivered pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(n)</u><font style="font-size:12pt;"> on or before the date on which such delivery of such opinion is required pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(n)</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">19</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Cowen Counsel Legal Opinion</u><font style="font-size:12pt;">. &#160;Cowen shall have received from Goodwin Procter LLP, counsel for Cowen, such opinion or opinions, on or before the date on which the delivery of the Company Counsel legal opinion is required pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(n)</u><font style="font-size:12pt;">, with respect to such matters as Cowen may reasonably require, and the Company shall have furnished to such counsel such documents as they request for enabling them to pass upon such matters.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(g)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Comfort Letter</u><font style="font-size:12pt;">. &#160;Cowen shall have received the Comfort Letter required to be delivered pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(o)</u><font style="font-size:12pt;"> on or before the date on which such delivery of such Comfort Letter is required pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(o)</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(h)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Representation Certificate</u><font style="font-size:12pt;">. &#160;Cowen shall have received the certificate required to be delivered pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section&#160;7(m)</u><font style="font-size:12pt;"> on or before the date on which delivery of such certificate is required pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(m)</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Secretary&#8217;s Certificate</u><font style="font-size:12pt;">. &#160;On or prior to the First Delivery Date, Cowen shall have received a certificate, signed on behalf of the Company by its corporate Secretary, in form and substance satisfactory to Cowen and its counsel.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(j)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Suspension</u><font style="font-size:12pt;">. &#160;Trading in the Common Stock shall not have been suspended on Nasdaq.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(k)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Other Materials</u><font style="font-size:12pt;">. &#160;On each date on which the Company is required to deliver a certificate pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(m)</u><font style="font-size:12pt;">, the Company shall have furnished to Cowen such appropriate further information, certificates and documents as Cowen may have reasonably requested. All such opinions, certificates, letters and other documents shall have been in compliance with the provisions hereof. The Company will furnish Cowen with such conformed copies of such opinions, certificates, letters and other documents as Cowen shall have reasonably requested.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(l)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Securities Act Filings Made</u><font style="font-size:12pt;">. &#160;All filings with the Commission required by Rule 424 under the Securities Act to have been filed prior to the issuance of any Placement Notice hereunder shall have been made within the applicable time period prescribed for such filing by Rule 424.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(m)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Approval for Listing</u><font style="font-size:12pt;">. &#160;The Placement Shares shall either have been (i) approved for listing on Nasdaq, subject only to notice of issuance, or (ii) the Company shall have filed an application for listing of the Placement Shares on Nasdaq at, or prior to, the issuance of any Placement Notice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(n)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">No Termination Event</u><font style="font-size:12pt;">. &#160;There shall not have occurred any event that would permit Cowen to terminate this Agreement pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 11(a)</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">9.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Indemnification and Contribution</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company Indemnification</u><font style="font-size:12pt;">. &#160;The Company agrees to indemnify and hold harmless Cowen, the directors, officers, partners, employees and agents of Cowen and each person, if any, who (i) controls Cowen within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, or (ii) is controlled by or is under common control with Cowen (a &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Cowen</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">20</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Affiliate</b><font style="font-size:12pt;">&#8221;) from and against any and all losses, claims, liabilities, expenses and damages (including, but not limited to, any and all reasonable investigative, legal and other expenses &#160;incurred in connection with, and any and all amounts paid in settlement (in accordance with </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9(c)</u><font style="font-size:12pt;">) of, any action, suit or proceeding between any of the indemnified parties and any indemnifying parties or between any indemnified party and any third party, or otherwise, or any claim asserted), as and when incurred, to which Cowen, or any such person, may become subject under the Securities Act, the Exchange Act or other federal or state statutory law or regulation, at common law or otherwise, insofar as such losses, claims, liabilities, expenses or damages arise out of or are based on (x) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or the Prospectus or any amendment or supplement to the Registration Statement or the Prospectus or in any free writing prospectus based, directly or indirectly, &#160;on written information furnished by or on behalf of the Company filed in any jurisdiction in order to qualify the Common Stock under the securities laws thereof or filed with the Commission, (y) the omission or alleged omission to state in any such document a material fact required to be stated in it or necessary to make the statements in it, in light of the circumstances under which they were made, not misleading; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that this indemnity agreement shall not apply to the extent that such loss, claim, liability, expense or damage arises from the sale of the Placement Shares pursuant to this Agreement and is caused directly or indirectly by an untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with written information relating to Cowen and furnished to the Company by Cowen expressly for inclusion in the Registration Statement or Prospectus. &#160;This indemnity agreement will be in addition to any liability that the Company might otherwise have.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Cowen Indemnification</u><font style="font-size:12pt;">. Cowen agrees to indemnify and hold harmless the Company and its directors and each officer of the Company that signed the Registration Statement, and each person, if any, who (i)&#160;controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with the Company against any and all loss, liability, claim, damage and expense described in the indemnity contained in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9(a)</u><font style="font-size:12pt;">, as incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto) or the Prospectus (or any amendment or supplement thereto) or in any free writing prospectus in reliance upon and in conformity with written information relating to Cowen and furnished to the Company by Cowen expressly for inclusion in the Registration Statement or Prospectus.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Procedure</u><font style="font-size:12pt;">. &#160;Any party that proposes to assert the right to be indemnified under this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9</u><font style="font-size:12pt;"> will, promptly after receipt of notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9</u><font style="font-size:12pt;">, notify each such indemnifying party in writing of the commencement of such action, enclosing a copy of all papers served, but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it might have to any indemnified party otherwise than under this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9</u><font style="font-size:12pt;"> and (ii) any liability that it may have to any indemnified party under the foregoing provision of this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9</u><font style="font-size:12pt;"> unless, and only to the extent that, such omission results in the forfeiture of substantive rights or defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying party will be entitled to participate in</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">21</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">and, to the extent that it elects by delivering written notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the indemnified party for any legal or other expenses except as provided below and except for the reasonable costs of investigation subsequently incurred by the indemnified party in connection with the defense. The indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel will be at the expense of such indemnified party unless (1) the employment of counsel by the indemnified party has been authorized in writing by the indemnifying party, (2) the indemnified party has reasonably concluded (based on advice of counsel) that there may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying party, (3) a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf of the indemnified party) or (4) the indemnifying party has not in fact employed counsel to assume the defense of such action within a reasonable time after receiving notice of the commencement of the action, in each of which cases the reasonable fees, disbursements and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees, disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction at any one time for all such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly after the indemnifying party receives a written invoice relating to fees, disbursements and other charges. An indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its written consent. &#160;No indemnifying party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding relating to the matters contemplated by this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9</u><font style="font-size:12pt;"> (whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation claim, action or proceeding and does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Contribution</u><font style="font-size:12pt;">. &#160;In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs of this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9</u><font style="font-size:12pt;"> is applicable in accordance with its terms but for any reason is held to be unavailable from the Company or Cowen, the Company and Cowen will contribute to the total losses, claims, liabilities, expenses and damages (including any investigative, legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding or any claim asserted, but after deducting any contribution received by the Company from persons other than Cowen, such as persons who control the Company within the meaning of the Securities Act, officers of the Company who signed the Registration Statement and directors of the Company, who also may be liable for contribution) to which the Company and Cowen may be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one hand and Cowen on the other. The relative benefits</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">22</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">received by the Company on the one hand and Cowen on the other hand shall be deemed to be in the same proportion as the total Net Proceeds from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation received by Cowen (before deducting expenses) from the sale of Placement Shares on behalf of the Company. &#160;If, but only if, the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation of contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one hand, and Cowen, on the other, with respect to the statements or omission that resulted in such loss, claim, liability, expense or damage, or action in respect thereof, as well as any other relevant equitable considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or Cowen, the intent of the parties and their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and Cowen agree that it would not be just and equitable if contributions pursuant to this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9(d)</u><font style="font-size:12pt;"> were to be determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage, or action in respect thereof, referred to above in this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9(d)</u><font style="font-size:12pt;"> shall be deemed to include, for the purpose of this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9(d)</u><font style="font-size:12pt;">, any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim to the extent consistent with </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9(c)</u><font style="font-size:12pt;"> hereof. &#160;Notwithstanding the foregoing provisions of this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9(d)</u><font style="font-size:12pt;">, Cowen shall not be required to contribute any amount in excess of the commissions received by it under this Agreement and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9(d)</u><font style="font-size:12pt;">, any person who controls a party to this Agreement within the meaning of the Securities Act, and any officers, directors, partners, employees or agents of Cowen, will have the same rights to contribution as that party, and each officer and director of the Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be made under this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9(d)</u><font style="font-size:12pt;">, will notify any such party or parties from whom contribution may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they may have under this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9(d)</u><font style="font-size:12pt;"> except to the extent that the failure to so notify such other party materially prejudiced the substantive rights or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant to the last sentence of </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9(c)</u><font style="font-size:12pt;"> hereof, no party will be liable for contribution with respect to any action or claim settled without its written consent if such consent is required pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9(c)</u><font style="font-size:12pt;"> hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">10.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Representations and Agreements to Survive Delivery</u><font style="font-size:12pt;">. &#160;The indemnity and contribution agreements contained in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9</u><font style="font-size:12pt;"> of this Agreement and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as of their respective dates, regardless of (i) any investigation made by or on behalf of Cowen, any controlling persons, or the Company (or any of their respective officers, directors or controlling</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">23</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">persons), (ii) delivery and acceptance of the Placement Shares and payment therefor or (iii) any termination of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">11.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Termination.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)&#160;</font></font><font style="font-size:12pt;">Cowen shall have the right by giving written notice as hereinafter specified at any time to terminate this Agreement if (i) any Material Adverse Change, or any development that would reasonably be expected to result in a Material Adverse Change has occurred that, in the reasonable judgment of Cowen, may materially impair the ability of Cowen to sell the Placement Shares hereunder, (ii) the Company shall have failed, refused or been unable to perform any agreement on its part to be performed hereunder; </font><i style="font-size:12pt;font-style:italic;">provided, however,</i><font style="font-size:12pt;"> in the case of any failure of the Company to deliver (or cause another person to deliver) any certification, opinion, or letter required under </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Sections 7(m)</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">7(n)</u><font style="font-size:12pt;">, or </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">7(o)</u><font style="font-size:12pt;">, Cowen&#8217;s right to terminate shall not arise unless such failure to deliver (or cause to be delivered) continues for more than thirty (30) days from the date such delivery was required, or (iii)&#160;any other condition of Cowen&#8217;s obligations hereunder is not fulfilled, or (iv) any suspension or limitation of trading in the Placement Shares or in securities generally on Nasdaq shall have occurred. &#160;Any such termination shall be without liability of any party to any other party except that the provisions of </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(g)</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 10</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 16</u><font style="font-size:12pt;"> and </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 17</u><font style="font-size:12pt;"> hereof shall remain in full force and effect notwithstanding such termination. If Cowen elects to terminate this Agreement as provided in this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 11(a)</u><font style="font-size:12pt;">, Cowen shall provide the required written notice as specified in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 12</u><font style="font-size:12pt;">).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)&#160;</font></font><font style="font-size:12pt;">The Company shall have the right, by giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole discretion at any time after the date of this Agreement. &#160;Any such termination shall be without liability of any party to any other party except that the provisions of </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(g)</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 10</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 16</u><font style="font-size:12pt;"> and </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 17</u><font style="font-size:12pt;"> hereof shall remain in full force and effect notwithstanding such termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)&#160;</font></font><font style="font-size:12pt;">Cowen shall have the right, by giving ten (10) days notice as hereinafter specified to terminate this Agreement in its sole discretion at any time after the date of this Agreement. &#160;Any such termination shall be without liability of any party to any other party except that the provisions of </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(g)</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 10</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 16</u><font style="font-size:12pt;"> and </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 17</u><font style="font-size:12pt;"> hereof shall remain in full force and effect notwithstanding such termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)&#160;</font></font><font style="font-size:12pt;">Unless earlier terminated pursuant to this </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 11</u><font style="font-size:12pt;">, this Agreement shall automatically terminate upon the issuance and sale of all of the Placement Shares through Cowen on the terms and subject to the conditions set forth herein; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;"> that the provisions of </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(g)</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 10</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 16</u><font style="font-size:12pt;"> and </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 17</u><font style="font-size:12pt;"> hereof shall remain in full force and effect notwithstanding such termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(e)&#160;</font></font><font style="font-size:12pt;">This Agreement shall remain in full force and effect unless terminated pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Sections 11(a)</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">(b)</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">(c), or (d)</u><font style="font-size:12pt;"> above or otherwise by mutual agreement of the parties; </font><i style="font-size:12pt;font-style:italic;">provided, however, </i><font style="font-size:12pt;">that any such termination by mutual agreement shall in all cases be deemed to provide that </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(g)</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 10</u><font style="font-size:12pt;">, </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 16</u><font style="font-size:12pt;"> and </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 17</u><font style="font-size:12pt;"> shall remain in full force and effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(f)&#160;</font></font><font style="font-size:12pt;">Any termination of this Agreement shall be effective on the date specified in such notice of termination; </font><i style="font-size:12pt;font-style:italic;">provided, however,</i><font style="font-size:12pt;"> that such termination shall not be effective until the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">24</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">close of business on the date of receipt of such notice by Cowen or the Company, as the case may be. If such termination shall occur prior to the Settlement Date for any sale of Placement Shares, such Placement Shares shall settle in accordance with the provisions of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(g)&#160;</font></font><font style="font-size:12pt;">Subject to the additional limitations set forth in Section 7 of this Agreement, in the event of termination of this Agreement prior to the sale of any Placement Shares, Cowen will only be entitled to reimbursement of its out of pocket expenses actually incurred.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">12.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Notices</u><font style="font-size:12pt;">. &#160;All notices or other communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement shall be in writing, unless otherwise specified in this Agreement, and if sent to Cowen, shall be delivered to Cowen at Cowen and Company, LLC, 599 Lexington Avenue, New York, NY 10022, fax no. 646-562-1124, Attention: &#160;General Counsel with a copy to Goodwin Procter LLP fax no. 212-355-3333, Attention: Michael D. Maline; or if sent to the Company, shall be delivered to GlycoMimetics, Inc., 9708 Medical Center Drive, Rockville, Maryland 20850, &#160;fax no. 240-243-1018, attention: Chief Executive Officer with a copy to Cooley LLP, 11951 Freedom Drive, Reston, VA 20190-5640. fax no. 703-456-8100, Attention: Brian Leaf. Each party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose. &#160;Each such notice or other communication shall be deemed given (i) when delivered personally or by verifiable facsimile transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day (as defined below), or, if such day is not a Business Day on the next succeeding Business Day, (ii) on the next Business Day after timely delivery to a nationally-recognized overnight courier and (iii) on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Business Day</b><font style="font-size:12pt;">&#8221; shall mean any day on which Nasdaq and commercial banks in the City of New York are open for business.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">13.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Successors and Assigns</u><font style="font-size:12pt;">. &#160;This Agreement shall inure to the benefit of and be binding upon the Company and Cowen and their respective successors and the affiliates, controlling persons, officers and directors referred to in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 9</u><font style="font-size:12pt;"> hereof. References to any of the parties contained in this Agreement shall be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. Neither party may assign its rights or obligations under this Agreement without the prior written consent of the other party; </font><i style="font-size:12pt;font-style:italic;">provided</i><font style="font-size:12pt;">, </font><i style="font-size:12pt;font-style:italic;">however</i><font style="font-size:12pt;">, that Cowen may assign its rights and obligations hereunder to an affiliate of Cowen without obtaining the Company&#8217;s consent so long as such affiliate is a registered broker dealer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">14.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Adjustments for Share Splits</u><font style="font-size:12pt;">. &#160;The parties acknowledge and agree that all share-related numbers contained in this Agreement shall be adjusted to take into account any share split, share dividend or similar event effected with respect to the Common Stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">15.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Entire Agreement; Amendment; Severability</u><font style="font-size:12pt;">. &#160;This Agreement (including all schedules and exhibits attached hereto and Placement Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties hereto with regard to the subject matter</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">25</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">hereof. Neither this Agreement nor any term hereof may be amended except pursuant to a written instrument executed by the Company and Cowen. &#160;In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">16.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Applicable Law; Consent to Jurisdiction</u><font style="font-size:12pt;">. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the principles of conflicts of laws. Each party hereby irrevocably submits to the non-exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan, for the adjudication of any dispute hereunder or in connection with any transaction contemplated hereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. &#160;Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof (certified or registered mail, return receipt requested) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. &#160;Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">17.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Waiver of Jury Trial</u><font style="font-size:12pt;">. &#160;The Company and Cowen each hereby irrevocably waives any right it may have to a trial by jury in respect of any claim based upon or arising out of this Agreement or any transaction contemplated hereby.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">18.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Absence of Fiduciary Relationship</u><i style="font-size:12pt;font-style:italic;">. &#160;</i><font style="font-size:12pt;">The Company acknowledges and agrees that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(a)&#160;</font></font><font style="font-size:12pt;">Cowen has been retained solely to act as sales agent in connection with the sale of the Common Stock and that no fiduciary, advisory or agency relationship between the Company and Cowen has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether Cowen has advised or is advising the Company on other matters;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(b)&#160;</font></font><font style="font-size:12pt;">the Company is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(c)&#160;</font></font><font style="font-size:12pt;">the Company has been advised that Cowen and its affiliates are engaged in a broad range of transactions which may involve interests that differ from those of the Company and that Cowen has no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary, advisory or agency relationship; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(d)&#160;</font></font><font style="font-size:12pt;">the Company waives, to the fullest extent permitted by law, any claims it may have against Cowen, for breach of fiduciary duty or alleged breach of fiduciary duty in connection with the sale of Placement Shares under this Agreement, and agrees that Cowen shall</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">26</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">have no liability (whether direct or indirect) to the Company in respect of such a fiduciary claim or to any person asserting a fiduciary duty claim on behalf of or in right of the Company, including stockholders, partners, employees or creditors of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">19.&#160;&#160;</font></font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Counterparts</u><font style="font-size:12pt;">. &#160;This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile or other electronic transmission.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">[Remainder of Page Intentionally Blank]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">27</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If the foregoing correctly sets forth the understanding between the Company and Cowen, please so indicate in the space provided below for that purpose, whereupon this letter shall constitute a binding agreement between the Company and Cowen.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s</font></p></div></div></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Very truly yours,</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">COWEN AND COMPANY, LLC</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Michael Murphy</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name: Michael Murphy</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title: Managing Director</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ACCEPTED as of the date</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">first-above written:</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">GLYCOMIMETICS, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Brian M. Hahn</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name: Brian M. Hahn</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title: Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="white-space:pre-wrap;"> - </font><font style="font-size:12pt;">28</font><font style="font-size:12pt;"> - </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">FORM OF PLACEMENT NOTICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">From:</font></font><font style="font-size:12pt;">[&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="display:inline-block;width:14pt;"></font><font style="font-size:12pt;">]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Cc:</font></font><font style="font-size:12pt;">[&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="display:inline-block;width:14pt;"></font><font style="font-size:12pt;">]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-indent:-72pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">To: </font></font><font style="font-size:12pt;">[ </font><font style="display:inline-block;width:29pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:12pt;">]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:left;">Subject: </font></font><font style="font-size:12pt;">Cowen at the Market Offering&#8212;Placement Notice</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Gentlemen:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Pursuant to the terms and subject to the conditions contained in the Sales Agreement between GlycoMimetics, Inc., a Delaware corporation (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Company</u><font style="font-size:12pt;">&#8221;), and Cowen and Company, LLC (&#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Cowen</u><font style="font-size:12pt;">&#8221;) dated October 7, 2020 (the &#8220;</font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Agreement</u><font style="font-size:12pt;">&#8221;), I hereby request on behalf of the Company that Cowen sell up to [ &#160; ] shares of the Company&#8217;s common stock, par value $0.001 per share, at a minimum market price of $0.001 per share. &#160;Sales should begin on the date of this Notice and shall continue until [DATE] [all shares are sold].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">GlycoMimetics, Inc.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Rachel K. King</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Brian M. Hahn</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Cowen and Company, LLC</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Michael Murphy</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">Jason Fenton</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">SCHEDULE 3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Cowen shall be paid compensation equal to 3.0% of the gross proceeds from the sales of Common Stock pursuant to the terms of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit 7(m)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:12pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">OFFICER CERTIFICATE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">The undersigned, the duly qualified and elected _______________________, of GlycoMimetics, Inc. (&#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Company</b><font style="font-size:12pt;">&#8221;), a Delaware corporation, does hereby certify in such capacity and on behalf of the Company, pursuant to </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 7(m)</u><font style="font-size:12pt;"> of the Sales Agreement dated October 7, 2020 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Sales Agreement</b><font style="font-size:12pt;">&#8221;) between the Company and Cowen and Company, LLC, that to the best of the knowledge of the undersigned.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:12pt;">The representations and warranties of the Company in </font><u style="font-size:12pt;text-decoration:underline;text-decoration-color:#000000;">Section 6</u><font style="font-size:12pt;"> of the Sales Agreement (A) to the extent such representations and warranties are subject to qualifications and exceptions contained therein relating to materiality or Material Adverse Change, are true and correct on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, except for those representations and warranties that speak solely as of a specific date and which were true and correct as of such date, and (B) to the extent such representations and warranties are not subject to any qualifications or exceptions, are true and correct in all material respects as of the date hereof as if made on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof except for those representations and warranties that speak solely as of a specific date and which were true and correct as of such date; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-align:justify;">(ii)</font></font><font style="font-size:12pt;">The Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied pursuant to the Sales Agreement at or prior to the date hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By:</font></p></td><td style="vertical-align:bottom;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title:</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Date:</font></p></td><td style="vertical-align:bottom;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>glyc-20201007xex5d1.htm
<DESCRIPTION>EX-5.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.7.0.58--><!--Created on: 10/7/2020 08:15:16 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit 5.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><img src="glyc-20201007xex5d1001.jpg" alt="Graphic" style="display:inline-block;height:32.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:101.98pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian F. Leaf</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(703) 456-8053</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">bleaf@cooley.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">October 7, 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GlycoMimetics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">9708 Medical Center Drive</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Rockville, Maryland 20850</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have represented GlycoMimetics, Inc., a Delaware corporation (the &#8220;<font style="font-style:italic;font-weight:bold;">Company</font>&#8221;), in connection with the offering by the Company of up to $100,000,000 of the Company&#8217;s common stock, par value $0.001 per share, (the &#8220;<font style="font-style:italic;font-weight:bold;">Shares</font>&#8221;), pursuant to a Registration Statement on Form&#160;S-3&#160;(File&#160;No.&#160;333-231577)&#160;(the &#8220;<font style="font-style:italic;font-weight:bold;">Registration Statement</font>&#8221;), filed with the Securities and Exchange Commission (the &#8220;<font style="font-style:italic;font-weight:bold;">Commission</font>&#8221;) under the Securities Act of 1933, as amended (the &#8220;<font style="font-style:italic;font-weight:bold;">Act</font>&#8221;), the prospectus included within the Registration Statement (the &#8220;<font style="font-style:italic;font-weight:bold;">Base Prospectus</font>&#8221;), and the prospectus supplement dated October 7, 2020, filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations of the Act (together with the Base Prospectus, the &#8220;<font style="font-style:italic;font-weight:bold;">Prospectus</font>&#8221;). The Shares are to be sold by the Company in accordance with the Sales Agreement dated October 7, 2020 (the &#8220;<font style="font-style:italic;font-weight:bold;">Sales Agreement</font>&#8221;), between the Company and Cowen and Company, LLC, as described in the Prospectus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with this opinion, we have examined and relied upon (a)&#160;the Registration Statement and the Prospectus, (b)&#160;the Company&#8217;s Certificate of Incorporation and Amended and Restated Bylaws, each as currently in effect, (c)&#160;the Sales Agreement and (d)&#160;originals or copies certified to our satisfaction of such records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials; and the due authorization, execution and delivery of all documents by all persons other than the Company of all documents where due authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of officers of the Company and have not independently verified such matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have assumed (i)&#160;that the specific sale of Shares will be duly authorized by the Board of Directors of the Company, a duly authorized committee thereof or a person or body pursuant to an authorization granted in accordance with Section&#160;152 of the General Corporation Law of the State of Delaware (the &#8220;<font style="font-style:italic;font-weight:bold;">DGCL</font>&#8221;), (ii)&#160;that no more than 40,000,000 Shares will be sold and (iii) that the price at which the Shares are sold will equal or exceed the par value of the Common Stock. We express no opinion to the extent that future issuances of securities of the Company and/or anti-dilution adjustments to outstanding securities of the Company cause the number of shares of Common Stock outstanding or issuable upon conversion or exercise of outstanding securities of the Company to exceed the number of Shares then issuable under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our opinion is expressed only with respect to the DGCL. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On the basis of the foregoing and in reliance thereon, we are of the opinion that the Shares, when issued and paid for in accordance with the Sales Agreement and as provided in the Prospectus, will be validly issued, fully paid and nonassessable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We consent to the reference to our firm under the caption &#8220;Legal Matters&#8221; in the Prospectus and to the filing of this opinion as an exhibit to the Company&#8217;s Current Report on Form&#160;8-K&#160;to be filed with the Commission for incorporation by reference into the Registration Statement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ONE FREEDOM SQUARE, RESTON TOWN CENTER, 11951 FREEDOM DRIVE, RESTON, VA 20190-5640 T: (703) 456-8000 F: (703) 456-8100 WWW.COOLEY.COM</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><img src="glyc-20201007xex5d1001.jpg" alt="Graphic" style="display:inline-block;height:32.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:101.98pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">October 7, 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Page Two</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sincerely,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">COOLEY LLP</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Brian F. Leaf</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian F. Leaf</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ONE FREEDOM SQUARE, RESTON TOWN CENTER, 11951 FREEDOM DRIVE, RESTON, VA 20190-5640 T: (703) 456-8000 F: (703) 456-8100 WWW.COOLEY.COM</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>glyc-20201007xex5d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20201007xex5d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !" ,P# 2(  A$! Q$!_\0
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MJ>YS,X:N726,]BNK_ Y1?$NM:SXE\FSN'2*27Y5P.!W_ $KV*VWQ6Z(69RH
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*^)CQTHHHJBC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>glyc-20201007.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/7/2020 8:15:27 PM-->
<!--Modified on: 10/7/2020 8:15:27 PM-->
<xsd:schema targetNamespace="http://www.glycomimetics.com/20201007" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:glyc="http://www.glycomimetics.com/20201007">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20201007_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20201007_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="glyc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>glyc-20201007_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/7/2020 8:15:27 PM-->
<!--Modified on: 10/7/2020 8:15:27 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="glyc-20201007.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="glyc_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>glyc-20201007_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7556.35618 -->
<!--Based on XBRL 2.1-->
<!--Created on: 10/7/2020 8:15:27 PM-->
<!--Modified on: 10/7/2020 8:15:27 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="glyc-20201007.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="glyc-20201007.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637376985270973124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637376985270973124" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637376985270973124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637376985270973124" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637376985270973124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637376985270973124" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637376985270973124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637376985270973124" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637376985270973124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637376985270973124" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637376985270983123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637376985270983123" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637376985270983123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637376985270983123" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637376985270983123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637376985270983123" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637376985270983123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_637376985270983123" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637376985270983123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637376985270983123" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637376985270983123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637376985270983123" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637376985270983123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637376985270983123" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637376985270983123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_637376985270983123" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637376985270983123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_637376985270983123" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637376985270983123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_637376985270983123" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637376985270983123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637376985270983123" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637376985270983123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637376985270983123" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637376985270993137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637376985270993137" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637376985270993137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637376985270993137" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637376985270993137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637376985270993137" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637376985270993137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637376985270993137" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637376985270993137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637376985270993137" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>glyc-20201007x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="glyc-20201007.xsd" xlink:type="simple"/>
    <context id="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Tc_VaH1S18Zvk69RuOsdAMHaA_2_1">0001253689</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Tc_Nrsf9Z3gwUeWA9ZUdsLcRA_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_bGNGby8nt0awN5IPUdGbXw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_BPuph74-R0O-QXyvg9jv0Q">2020-10-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_k5Oi93dxVka4qReMfg8bpg">GlycoMimetics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Tc_8Sgbgx9kYEeR8dqntphOJw_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Tc_McKk9gvPE0u5xwJ0LxqhQQ_1_2">001-36177</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Tc_yI4GQP3ao0KZ3IP6pI4LUw_1_4">06-1686563</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_RJqL-GmxE0W8Zh_OQZftxw">9708 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_Xssuo2XcbEqZJTpQKlVPMQ">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_6X4QLop2OESb8XyHF8tdoA">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_zfnYCtnzvkq4ypyxpG-iYQ">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_OV9wMjeis0yhAG13Vj6EtA">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_XWYKhygIWUqLaS16xA6Izw">243-1201</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_JCGoSHVsdEaGsWp39mgiMA">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_AW1-GrfTy02lxB5ST7qDoQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_oxIht_zao0WAOWpm8rPeuQ">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_24NtY3E_lUK7grcuVUdaKA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Tc_VwrFh8a89EavCOgzwYmtRg_2_0">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Tc_9hl3qBhNoEGLvnY3EbLXqg_2_1">GLYC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Tc_JTm3HZES8E6uRfU97ncGLQ_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw"
      id="Narr_m9qMVBR8TU68nMcH1iFtGA">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139713075597896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct.  07,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GlycoMimetics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1686563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9708 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-1201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLYC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MI6J//X7W*+F?&^[_$L4/4$L#!!0    ( /.!1U&7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ \X%'41PX9>H_ 0
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M 5!+ 0(4 Q0    ( /.!1U$'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ \X%'4>@-&Y;O    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ \X%'49E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " #S@4=1.S.YT#8$  !?$   &
M        @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ \X%'48.II0/4 0  ,@8   T              ( !>@P  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #S@4=1EXJ[',     3 @  "P
M@ %Y#@  7W)E;',O+G)E;'-02P$"% ,4    " #S@4=1'#AEZC\!   \ @
M#P              @ %B#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M\X%'420>FZ*M    ^ $  !H              ( !SA   'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ \X%'4660>9(9 0  SP,  !,
M             ( !LQ$  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  _1(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="glyc-20201007x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="glyc-20201007x8k.htm">glyc-20201007x8k.htm</File>
    <File>glyc-20201007.xsd</File>
    <File>glyc-20201007_lab.xml</File>
    <File>glyc-20201007_pre.xml</File>
    <File>glyc-20201007xex1d1.htm</File>
    <File>glyc-20201007xex5d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "glyc-20201007x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "glyc-20201007x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "glyc-20201007_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glyc-20201007_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "glyc-20201007.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "glyc",
   "nsuri": "http://www.glycomimetics.com/20201007",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20201007x8k.htm",
      "contextRef": "Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20201007x8k.htm",
      "contextRef": "Duration_10_7_2020_To_10_7_2020_Nw57VaU_jUi2hIqGiDiscw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "glyc_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.glycomimetics.com/20201007",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-20-011405-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-20-011405-xbrl.zip
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M' ?7+HVY'_V-IZ4W60;QJ:"J#:D%-:<\!4SU!;\5I*D["/MJ;YKD,MYFR#=
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MB];*#:3=.E#7[LO('7$D_\DW.Y7UOOT?4$L#!!0    ( /.!1U&"9C\=C@0
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M<9]A2EOZ\=FQ/BPY@8S[9_GZQ;5YK'_K+]6/4N:+$-G)6=5+%>%G$U5>"QY
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MM)2]3(H]\/S!'(5B)SJ\@[KXGF\6!-YV8  ZXAAYZ)_8>L1>, C4AA[KVK]
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MI-R8R6N'_MX,?0^[5Z;CKL!>T^:;Q2H$K3JR?5 E]U_M/L^'#GU3YFFUA.?
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MM6T-RJJ;L>Q+49(FMUXPV.7L-%'4JG7$<\_.?N8<"*6M<<UKL'6=;XUKU.V
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M[;JX#'_B%]#.@(<J>0IX>V7#VU+5Y>P&NG9IW=3,N8^R0L>,M/JRFC-$+AF
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MWZQ(NJ)S(8"AOY9<V@S3%Z%X"\)K:=O#NZX,F@MU6S]2A_AF]C<*+>V.E-\
M@*OG0NR^45UO[*GRV8.#.H*[9%0>%\V0OK.-#ZS/3898QY51=H*J6:V\O+P'
MTO-@NZCP9OQH074X:LX2S@\:F?A=K),SK$$V6"& ,J^6SED5.#*>V)!3IKTG
ME4?(")(IEWJ+<ZD/IUSJE$O]?G.IQH9I4:I:J*]+R+;(TKGD"CG@)=RMF%$L
MA=^-%*THET \#NK0H?*1A!\2M"HJ<.5"BJC+1XKTTG/*I9);E\^;U:QTR;\V
M.^AMIQQ*AD!&H08L*R62LYW R8C@%@*;/@.TJT5U41!N3BN )6.J6D.:2:53
MJ5IS^2JJU^E2UMJ_+1J*%CVZA._&JS27G!AZ\PZK2=G^(YT L,41W8P4L&YV
MJN@+,+PN=-E#_#"9ZJ%1N:TP*!/TR7%JUPHMX*9AE)>Z.W!8%0=BOMQNO>9T
M7;/IA8);_5#MJ@,!5<S9;;1;S/FCL^>5&Q4S"<3U@\LYM5*2AX%ALH"J>SE[
MP+3-0\S&H;NQG8 86MP94C-^W'#.AZ(&RC)HT0POM&/I.[L59V8K;L#5>?[B
M];NS/7IQ3N&'L<,/ZQLIX9J;:,);2V#^17K@N->X=F.MW'6J:(DM$0Y8[)76
M6K=D&-6'2-('XHR&.QU?;<C1C1>D%<6=TOL^>T!X)BME"E#?6',"PN^1SCE*
MPOFOPLARJ[<O15R1O\^T"5YHMG35F,L0D.07:5DX\AW7NDQ!.[&,77$Z))0$
M8JHI--37&%HX.//*>2B X#0% W-$C3F&1+&TG4N0%K;#WXU@1?RP1.R))10D
MAJ64C1E9VX+XX ]=>!W7\-.)&K<J>I^MD:/=RNP&+ 96[3I:WG]C(^VNMSIE
MLH[:M]5@T8RW:XU6HPF1X4.*3=))33#VH')/^9:3S4!K/=QD6>)Z38G0&Q#>
M_QR-_0%LF=<F1O,6KP@:WDD]WX^^W3@-!:4,$VD19NE;A#[0Y=6L6M8K2VD>
M@J;ZQ PC>W==IF0^U63,:Z(1[5F!A[AV*IJF:F$5Q'EB6QAR=!G+"8B,1> $
MDL 2*]UECOCK^/UQ\!P1$CB3IV5S#C+ &O-PO6^HU_?SIWO88!+>Q5V2!3.+
M&(IEBMJDF,.B[N0!B.E.E6!-+D)-<ZHD;W!!Y5-V-6'0ASZK>A_R*.SF%EM(
M%CEJY+9@=DP]P=W=/%=4:AFN:6Z.O[2M<5WCP=6E7%1R4<R-<[6"TV9@0J*T
M<]H[+U$>.DK57HD>?XXO! ?>0P2MG ^YM]*950T*LB7 +UE$%P5WHH63E'(7
MS++)V/Q!@#)?":TXOSHZ/:F#L=5!.1KE5_0I>!E=!K8-U?74 -XFH4KVD@ M
M>4/>K@AOQ%"NB$E/#%QVA26M%=0PLC*IFY*P;R6]@3_J$AF#Q4-@9Y1$8E ?
M&K@D(UM@//"LI,,J3W\%$94*GQ#<IKCA(:ZC#??.X-:9IE&2RCJ&R7"$"\EN
M^=KF40:SR)(+@C&*BY#6W6(U[OU-UF E2'^"XX&LPRY7N3*.&0WH"*.AQ:<8
M!OS_/QO\@@300L0GE UF>)D-# [J16)@&$Z@HK=LP11D$%G:*!3T'W>AH >C
M^$):'# V B4?QF@^Y[ Q3I">H_6&4>5G4/%(.OP,BUY]0M$E7,Z,(#'JA$Q"
M='0A6HW9PP^/P&N/)/M%#E>MIJBF9:RXZFQK!5,772'M>S#KQ#;+FLZ]DIHY
M85@'0Z>Q[%GB)N%3.[*Y=0_QM6BHB'!8)5$N.(SN3*C,'_YR^NO]$Y>P_BN<
M\BDW^\5RL[],N=D?)3?[S21B)XWE:*QZO%JIJBGWL_9[2=>&*X7\V#3A_>"5
M'!3@?Y84O0155ISG3 -J;%"TZ[#65BPMBGNN"[!54S9>.02\0MX):9V$GZ#?
M@A+"#J S+0><8V"#8.9,/%A]9'**,G'(+*0(=UTVL4E"PJ[ =I<;HUE-S1'^
MPF#F8&9)CN"]>,@RSPLM$B*_(TN3BX3CY.CE6PT=D"%N.>7P:SF<.@R2F)JR
M5#>.)X9UG)$L =*A,D)85RKYM,;\/2<&[&,Y]<FJG^,$YEF4B50O1UO-,K+8
M>"_6N4-SV?%2MI24Y<6E_DWJ$6#Z6!Q7"?W=7L&<R98>73(U(R87WY88@WM?
MDZ-EXV*OP!Y="[SB^D$*/&)U]#%IP1'Q5]LKT03$""(/EH9]8A(,46WS64Y>
MR4TJS:.& ;KV;%?MV:V<V5D0I 0C*7+(((*.WPG/7T1S%)1T!Y?:3YG>MJ4!
MP'2)1K]$%V-=HG<2LGI+ *T/3@YRKXMC4^Y&EK.E"@]:INN*#QF]ZDBP8#X'
M*-(UM5+C2H J"#)B.-ZGW^/VMHUNM\;I?(]]OB_'.M\NL>"U0]>VW>CNG"Q]
MU!A>ZSZG3W-MVMMB]!K^R[$;*KP<(K-S>BX;];1S4VLY^<)>QE+?7:G0X<V'
MT> $S[F.W;:/D0H2A_]X<)+=GL0]O8AOM&?SE^WW3#1"7Z:U\22:QA9-GT:T
M7__*L^ART60!U>@)OW%ENP*\Y9#M'KKX=9)*;MSJT7Q_*!NQ, B\+%3,66C0
M1(KP;3^*[&;P2YGGUF5EP!+R/);$"?4=EYG/G9F'P7FZ0"@X1CI1+&@[ 18V
MYCMH,>=5XF7;T96MT[G ^R[ _&56;4EWF?FX!KM]HFGX4;@@")+P!9PS>+"#
M>^#U$*9TLR3D$+>F^YAQ=@()%^A4-5"D+F5,AA=5QO"D*+$1$,A5G-A<B',I
MHO[PH1M1?\SN^X4SY1G:.@ANGQ$* &8)0T?IM,@:4DPR[S#XF,X_8J2V9[7E
M,Y,H&ET4;<9,2[E,#:^*'+32RXB>P%1@E_LY!%YC@!:=;=FFC'#B/35GX6F-
M>R@D>O/0&!@LXX])LM9V=J7A,.NS=)X0WFS.F5V]9J[KXW"@V;OF9:\X9KFB
M9<KL,J$IT-0,ML1Y>+P\TLZ]I[%MY9 (<,BK'TQ WPV]+R*VV="8A9:SPX6J
M46T,527$BO+R\=!4JQ$<P*G(N--%)H#A&^BET'_R=@:R,3O)-DCQC(N9L:U3
MXE>X]"Q*Z%>US(K8N*51.4MK:KXVX+[V<<3W3@]50@_JW*CC3@F9Q>).0GET
MH?ROFQ+*;YZ?/?ERAN#PZ1JP_2)N'N*9@ LL%S,,65X2Q_8$-U4,;%L18K:*
M%!3:!ZI]0^_$AZIT/N,R1#*3"\-Z1(]ZB@R0]<HQ1C]@<+4I;Z3XB3=I]\8O
M;:RI.L;#$>:&X:X3?.(6PR=^G> 3/PI\XD<L;1=KRAC4IKO?4 =IAR*+JM(P
MN&@<?TM(0T@!BJM%%Q%8O%072WEJ?:'HD+^+%!Y^P:PX5%R><TF<ERLHE/(Q
MM.TN&O#/F1](_ <QVB1H(!QNY)#S0ZZKQU 13-;9Z-99%(T,Y331LS/;W>3]
M!L[!ZGJ9YU644D0<*R<K>@X>2 /'A/.51YDRH@;HL7B>L/BMBM(\B*3:BAI0
M(85NLE!2R7?@30:G]Z*CTP<'BT.]NW]*K^=WQD]]Y[B;MI3=2ZS<4(V3-P8:
M\.ZFUV$@S10IB;)';L0G(#=)?C9=T]+M%RE=;K!S-E,<7$C1@/F]TW21[>R*
M)*19YI0ZRR3EA13G8* 3 X6Q@R! 7(] ?2J>%$9@O?PJAEQ,2_4>JG2XE!$S
M!)KCK#V_,?S O8'FK9(\B:]V7L3A&$ZQ>AD3*5=:^SV@>NL)*/1#N26#ZB)Y
M^^?9V5MEEM:;HGV%%&V_,+0E&G[%#D05*P_V(\CAQF=3@"67G-D76!1M:WAQ
M*&=)EV)HB.0J$;Q*TWP.*3A](*K=K28)<*%E&BZF2E G6*I+H)5V^('=NH6D
M)/NJ0RQWII$[.PL<0K=Q@3L77 P2WBH#.*7=3&V@AY2[Q+Y[B'O)TFIIX7(.
M \ V-*$E;Z;FD?VYCE51<4$?@OA,0XX*\P<;L"*51\#<\P,L3'3*K2_!^B68
M@PR@_?S=%^Z@U2D514^,.QH?:D4[OED[G7[NZTA <!D03\54IB?,Y$>,+0:<
ME*4?I=*^\_GP\T8R&4>C&T>SV5C&T5.FZ$#K7&(V^U!HMPRAV#Y,#E4E:A2\
M@KA!!\/8.<,F3G+8J\W);'"-@<WNIL!C 1)?/3Z'#-%!!2:$;A:$[S#%K^4[
M:3$/45T;7J?*H(01+R(-Z6:H; <,-KKDK)M"'B>V.,5X^0HNB*$"YZ>+9A+1
M0XB53MM 1S --UPA-O0P,,7V@\LUM$B\Q7[/;>157C69Z:\!F[AJ<NF,.$!M
M854[:<8L*RYI7@3PG@N;)-9.ES1,N\&#194VA96 =F[\S)=1C*0Q3'?&WG/C
MMTQU#G#? 9QDZ.@R=#X?#YIIB!7V[$)0U0W26H""3JI:+U<RA[<20 +IY?3?
M-:IT]_AR>@RNUBQ91MFB@R'&:XA6_C;DY0VY@SK&]SQ]FO<'FM\>"42"8FF5
M-^PZ%?D*#P+.FRJR0V?!MC'8MUT*!*Z4J6080=[5!<RA"EW1)[1V+ T\GD6F
M7+(9\-!V5H7O+Q*2NNA&S5,,>Z%O0JT%0(B!)X1;XM#F&]GD]XP-AM=P6T<*
MSND+P?W@BCSNJ8+V\U 6[BM'F(#S_'JTC:^L(G)F(W34)>,R_79\> -PB-3M
M@/@!TB+W'F#?1,AEK[K=?W$WA[.%+Z1B;L>2RY;BQ&M6]OSIF2:7#0O+-O(5
MRD9+8P;6IJ9,QV:M69MHF)-KS"--CE=K9D3@L@+9KA9+"8VG?2S@\W(J2"#L
M_=BKR+7(7AKFU:+[>35M5>T"TQTGFO,IM@ER%:T2DIQ34NT6)]5.3Z:LVI15
M^WZS:J[Z,)RS[.PDL:%5[K'/B!YZV<!P38[J<EE06BS%,'/MN6<#ZOTX>)$'
M32743^*:4*MVV%I\L>^@BF;K.J0PSEPX6MRJA8&WAAW%::H:ME<QX)\<,* A
MR'78R-COM.S4T@#G2JJW)/BO),K@':;T.7@+7K#&;O$M9WXXUX $?_W9& -7
MX?Q WURIOW*G#]86PTR;W4NS$&3@P+Z*%%$MG%1%6K5Z)QHOP/N2,"@Q.PV*
M2(>=S>AFJ62F D5K;X+K+X;Q+M,C"&64-UA\T9")(N6).C\?0XJ5PE6#>XX%
MX:C5I6EEN]G87B='(9MA'[J2/">MD59<-JR"Q!G4VNHE%VSJ"M,T"E7**<1,
MK1A;7$'=9BC&MB'**@E[T'5.>.).*EHK4-!YD#FXY.)#,R S=' "FZW#GZ(.
MHT<=XOBF4(?//$;@77'@>U- $%VZ^=*7INYWN!(Z;$F]U1@^/U@HWI?#)PH*
MQR&_9)WH%:-DC6%I!#]?-"(\G?7TDC6,^!\.Z_*55*31:D;J.$JQWUQ3@LB$
MG<)IA^+7R _4PU8_P %A_8FX22-B_;Q,LQA40N)&9?M>VU:P$B%UF*,E[%N%
M9#PHJQQ\!#FHV9&W%,+VUXM@OH3OSLD8X'7CUH<4;D"ODGZZC"H2TG7Q">,:
M,!>NI0M!'?TK*N.BJ;S?KA.,H"3-2CH)Z$^P&:B>JC;:_0:0[G)4:0W\6_:D
M@$F4^3X]J#P(59N%U"K9Q$3[Z8#%2%-KBJ\:;!%6XQYQ35 %"H%ZC:%(+2J\
M#I3LQYP 6PEYG GLZ^K9W/R*]XFRW5>8%;:5%'Q?\*S!^JDLH2M#(0RRWCKE
M*XPK6PGM?$]+C1;K<:=WAC&)5#.;>ON6G2C%)-;0Z<Y>^6?;H]1 D0E&QJEC
MO2)O;2XVHOM"+]IU62*V(G>2,73"--5-M7)1[\P1K3>']_TKR2L2:&L?<VY.
M>2BQ:#A3YPI\:4GW/LG>68;'+N6-LM9CPCV+TE6HL J*&#:,')1?.:79T5 1
MB9U37CA6MO&.''Q&UR!<4C)(5E57E..(H1:Z^+_6\IXV ))7B;RY BU*(HQ/
M732*ZP%LB&T'13 (Z;Q9ZX_>U(1XB=K'TE]SM$'Y#[ 6&.J,HU5$2L!0:=K?
MT #)\\ :*>(?K>'5>;*IQ%4 '9Q4EBZ535\.=*)RPF,XH^X&/%&V LB)T!XI
MW%MUGDBC&VY^2"'?EM(-]7 8\V%0B.&)PY8^AM496RV$VF@!SZ?Z)+YK'!*Q
MD;5?UJ#/;IM$?((G?B^9V%.UM%M_#.6\=8^[A+X[9_>2&+[]X]J]R33XGNMC
M>_<@2@XC*5(8HPTRC66)D157NF8H&UHMG_9M".+$GVG'R1RDCK^V"XF%'H<^
M3T#HR%X0@A<,0\ C-$_CG8,9<O!#8Z$Y!EIH[H@$?4C-[WP;1 0[8?PN4_C5
M EC,:MX\N-(I0[ =4=6WTT,G2'Y]VT[21'=ZJU,+IU-JX4=)+7PS>80I .8$
MP))D/,+3.B&K#,0YAJC(<KU>+0<8AVS!FLXWJ%6X\0W=$S2:T*G F#2"]C%7
M0WJ=_Z'NF]('E%&<P"'XZ/[;Z^"(Z&<L%IBCST^?<W]L?_0%0763&CE.$$>?
M1ZND_9EYL=[04-U_MS\$8T0^%AT6$A""NN0I5C=1A=N[A\$[&L^>9 )4XX#>
M4:X+7"SJRZBDWO*PQ&2KD)M'1'?^+K4V@U<'EQFC9%$=H0-3474:(ACAD6@\
M!LOBLG]S)"M2,_.6,T7C8-GHH;<5[A>;G \7PR7O%/8WW**-"@K V"$W,%^0
MI9F2IV;R?Z%4"%3:=D[ 2X<W[]'T[SR7C^^Q\U?V(,(HM2T--&@PH=[G_B,$
MV64(K\]HNR42OHV,U(NP%.LTIRB$>+MI*=T.,3-9)82_-T=A*6ZK7^7HS0>V
M%U-P>!S!3W *2ZI6<%&XC.#7MH.7T(O0 =IV]UI-@<D^#RT9C#?)5F1#O@E^
M"SR<VC1)N0AETW J%DG6@NU)4,2K#=7^3&98?A%^MW1F^[3*@;\+;X%IR-AT
M4=QFQZ]F_>@ZF_S58?[DN$CX[)Q3TV%J8%)(GICW6X@3F/;!V_G4-JGBI7-=
M.?[\ESD!N@+8<$Y5B0EX2LP-_[GUN=OPJ.B!TU#A+'!/*VIV'79&/O-\2([3
M<-:57'F&_SF@3CEY%"P=1H;O FC@L=B,E#3]UD"K=_6Q,*P4:B GID(!2UPK
MTS!\R\&5=1YJ=M:%9>I#T6.VL!+Y[< -N_+U>U9V:536XA.8Z:PG%& "GOA+
M[ZRW("M:[4T:T-'>OO)V=;=C"/D&CS&$@M1IM]VOJ-F.PLB'Z2Q4*F&DC5T,
MG2FAI<XR%]4(&GE=285H32@"6R&)J<!HD9PW41G3D=UVE]Q<(*,0I#\W#<XI
M.<PQ/&5J&"198"P&BCMKRU+O>GQF^].@I_$Z/@+&P?$Q6*BT5$88M%"$W4_6
M%CW5FK'2VAF@)?$YPW%U5WL^Z5Y[J9:<OO<K5L"HK0]Z0-)L>*_!TB$Q1QY
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MI234A8@8H2JP'V63V-5B(D53GHL<T*3NL#,D9OVIN53[ Q[W#3DPI(?M#@B
M)#1U]TI<@#_XEXN&KQV-0W(Z83^R)&)F%MSEWN42C)0[$EJ$MIV_<TK"OU-]
M]Z4GMR+ZVTNK$5B"K!H?1]T'E.P]!SV^G+78/F>.!^(!2@%7*[=_B#BN2%:B
MQ.(&'E?E/JUP*GP%,$H?LN"OQY_I@$M@8R\'W':$14$!AH$;EE%.AWY/D+KX
MR3']NXG/]5(XCPWEL,FGB-J5FAAW.5XG$L];G3VX/V4/?I3LP3>3*IA<(+>+
MS<BD)WU*^8OX/"T[[59Z/=^>TT-QW=ZI\)JUJ5G4A^& T&8X#D3+9$==V5%3
M6YM"(B8^:AYL)=X7)\W#-"_D"\F[$:R3YHVLI1>:<LMNP/;*"CQ,/2T]=H&S
MW*39Y97:F-'[V!QR"=BTMOM!+HXV3-) NUB7<0)[0B4_SFX0'P<5,9TG.?9?
M,K1;:'4+'1NLD+2PZ0OG38&M\:F9;R*P-> 1X:VT@ODS0NK=]%H>BR!C@/Y5
MWM:\6#LM]X:"W"U%XHALO',[)*K4&><L(54*60P?=P"[/HB/.$6&4V#7 >+N
MK1YWP=_Z:W7E@%U_W.EGOU/64Y>;@A^4@YQ3G6D%(EZS@D9=K+$KA"0"A3Q-
MU022%5%+&]4RJ'J[\3KG80H;I$*8J)-T5Q@G)X0R4#AZA/V3Z =%: :)1K&*
MDL@NDQIU+&^DJ0+MW3BQ%S![?_LT5&V7P,MY'SBI8']%#KTR+O>V]_3C-,]+
MW: G+!PEL"<]-#ZGXEAZZ%E48E*PLK+S,Q0-!5C%W,$(H#E)PBULP%!(%YIP
MX%A%C2-?I M=[@2:J1]=5.M1/WT0K&!4RTKRPG2>&23OW"4C4(0G%*1IA:TO
M0625U%8R0K$G\[>Q0ZP!8F4 9^Z(WN-)6/4HF'70!-1](LC3@XC5&'L:#WZ9
M0!*WY&J-QASX3,C'KG6A;']!ZFLH>*BMI172);%T.(F55[M-_Z#,EJBL?!9P
M8VKXY_KKUYQBVZ*=BDX%L<?)!HV?%UE67.*=-8QOJ$6UN9BJ/+C%E(83( *1
M91AL8.4^W>E%AK*HW0[3O,4U!P\$I\IU+-)< KDA:H5<VC#_%M.5>-Q]0)AO
M^RHNDV E]$DWS<92<,<'F$(<;\P&K.&4A6^V):3U*;NA6?B<M@,7M^08/CR(
M#W<XB)UJ/I=G7+:9>CX>=*W"P+2PT*Z0(&=GR$=H^(2O*KFW(0I3:+^.4B?^
M9MM/VUIY>,3!!6[5+('+0L5W%[K[SB$U&V[MQ\6PW:U)[RW55GK8(E70_KH=
MR"!H,;AUMB%M),7=CL^8LZ$4P?#"W7%42')/7[*DR+ JAVX:KC,2RKR14'98
MC&W57^]WG;A@5%7%/"5IS Q89H8*;S:6BK:J=P\ /]GAH7[^XO6[,_BB>'7!
M<VPL/<>W/\5;K!V/T;#WW@=C2E?FH+%6*>BHP,C^_?1N^.#DA+<)SXFLB3,/
M,[?.>?4GH8,G"TYHZ=MO>W 2PL6;DI"W.@GY8$I"3DG(*0EY>WV9T1BA_^*H
M\%O&#'].,%KS8J_!+M''7<$*K;^IQ !(E!U=B-A:@SL6&K;I.([.4SI^_0%3
MDK_'R.[>V7!V"7%YYZ::J,,XB,W&<M<U)$=.(/6),2=CT!R.&TK>NK:/L.4$
M5S^]&PH6!T)L<:EZX*Y\ K3SX_0%V*74_XLAL,0,O,!@&^4=LRPT/9Z=7^'_
M@IE[7@KW#?;D8T^#/^&WS>/FVHEA!AX@I'2#T]WJ2!Q43[V1[_"UR\<*SW'L
MU%0BU$\2 &RQDO]DAQ1JG5ZEJ%AIFH?E"@XM933G;DGN=S\O*;!S]2.9[;++
MNV2KC5> X0?UW&4G3:U(:V="V5U:!;,B[AKT[R@6O6)^GZI#=_F(='E)>;WY
M.. TL)L6O#?F?HS>H:$I$.1:&<*23PBV8!GOC+OG:=YADC(3>"1_*92?9D7>
M. _@7X(LICP)K84T5]O:I\!$3MS*%N=H]FP2^D)XKMB&"X-54IYS?(_WJ'2.
MX((:X]5>=,4M8NK;U<[LP:;$\!?ZHMCTM2+'D*?:BT>-X@*K&CN).SW#/(J5
M>/9&L-&)Q5I+;I_F%B>GN39FD&C#%FG1M_%\E4.YZ(KFA4N0K-;F]1[FHGU@
M]'2'W:,C5]\"6_ O3L<)^%%C$U<M?;B38*)1#<@E%8<4J2LR[K"(@9D+\/ 1
MMYV<%S7'$)PH,*XT*)"X*+&E,2CB @X5]NK%L&)RGLZIKTPN//#K C-^B(WO
M^;OMLTEO!DLAQ]M1!%(@KLED^!JGDKOTV^T=9;X?5;J@\? K9GDY;JO<?E;L
M$[)^B;_C]+0-<6%8&VL"E)23Q$QOPD<JO*5]E>U\YW!+JEH546LY"K60)/+;
M/=G\T% 6?\KEC,\N/AK5KH *X(2[V,/K^T$$>Z"CB!)6T2>M#*4/TK1< G"-
M8T; ))SSZ1J6)(_@VG3#]6Z!;4]]K<,'8!JIM4MMX5?]M;;2C->4.F'T,II+
M:3Y7^$19S4I/^!8DS=MNNR<VJ%!K.7RV89 E=>VVSC+@!:NG5/_XQN74O^I&
M+^MHO-A/FR1X"@K@G%!.3PKL.DJ?O):'B&Y<7]ZB P^>RXN4Z3KWP,%4>6@&
M5287:>(VMS:9&P'K1.>"E>NU]:_BV/,2F/@ML&LX@6G2DGA5&$YMKRL:'\+A
M8;$;#K<%-2" &UD:!*QM-!.J$&,*;Z<)U[*@&D%,%/5K:\.?+P^K0A]*U@6.
M3;=W]-N;C4?!*G[N<\E[O7-R[%:=?58YA*N-W0X?A8 :N418^HJVL)JL(,6J
M[!$#)@HF5N3:QC&=%'P?I-,:EKN0K@R#23GYC_E+RN-*9I(_[SPAM*TL=#=G
MVR(;<DIFX)U\QO;RK@9/885_NS.[8K\DDGL8BADTM);8%$7SW*%28G'V,DLN
MT !@ !=OEV0D^ZI<R?6JEV71G"^=]IU^M+J'ZIRJA>'G)*]8E*ZC#6W?$*E]
MNPZ&CEV/L:;]0B0K+^&A!AMS^7EYVG1& _<NTDX V<:@9"^QIH;]8O1*#3S6
M1*%D8MRZ@=PLKW,#/:K[KBGA>ZL3OC]/"=\IX3LE?&^O%;8:SPKS&K6@NJX>
M!T^L'[Z[L?6&G!HP\IGIB1!,:5G5@:F!>DK4';DP3M+=-.[$-A>,%!J'JAT=
MBXD0M+VJO4M;,2JQHMA*%\.VI=)HW]>X>;$A^Y +?WI D1:HF!WV9<AFV+<S
M8B4<83:P/K(T] :EAR'B=/Y1J"^=]RK:U7V,K2"2D+NZA ?58:NBZ*JBK#V7
M2JCB>3=QM?*\B91Q!^V6YW!9@M.3H_]G@,A&^6/Y">A82VB-?$GF[7$>\_\.
M/@:3 9C D*&TA_ +C #]\"@EBC4EN5DP,J_-G^_LO_M[,<:ET">)M9V<&\5Z
M 6M9!7>/3^[BD!X>GYSBAN@8#@?&+SZ!-J*P..0B9^.L*$W5G_7W:5^E^@@#
M$1D6-5>"<V83F=;$!.AOPI_H$52[^Q6/>_+M6F?EV.F1'X 4WP(W+HCJ&E96
M B\U94N^9D7!$E1Q#7=_M0M(6?V@RR(XN'L8?!"HPE.$*DBPMF?U$.LJ818G
M+N5ZSFZ5O9-)\5;)I7^U(FOE'I8&K+D(2WZP5N@RHDBS,A'VC8O(ICA.7L/+
M2.Y'M;@N>=&-@<.KA5Q _4=Z2REC,.7N3$A-F<,(-B)A0D)\F[D3^'[WJ(@[
M5O6%WFTMQ@&_E<KVB7H(7*L\CDH3W_=26["&E 'LF[PESLWAC#A+T?/9KP]4
MN,[S]V6!I@7S]@O5$@9&-MM/25_*Q(K_80VR4YZ2D.">S#!$A$2I@/4F!E;3
M!T!7@%#O+G-+&_?QTD99XU*R'HS!YK:%/CRH*Z[<BSA&^<0NDHEB*KG+2]ZY
M5[XU8)-:0EJ-<*7>1DA7(ZB^88D>DB"*K4CJ%#KP0DWA\=$=LWPT.B"JZ'C#
MF=&OXH29\"GB&P_N=0T'LB5[Q5<KJ-F3NS85=VQ6:EC3%UG?R'4D/63,#Y'-
M6$%OHO=]TDBH@9CP4TU]AYLCN"RQQ4.NV6^&U119L@E>OGP;'+1,[*_35AB'
M^X3+>*Y>!QNE-SEY+0'B6NEH7A=.05DHU*TKJ4N<,9JB_\-MLI*.#+2]#62]
MMC!PA X7;+8)P>^)4^2&HH2C8>@,I>$#/7VK1ZM&V>X\I]^'<0;[!W9)8P+]
MIF\MF[J&F[DOBA0&K0/&="%]7I<@/0YNQJ^4#M$O:1"[^Y2&7X/Q+4[;7\YE
M<Q^12&2Q'MHN2<Q(]EJ^BZ"3*571RO"&8.^_!?'#8Z:H:Y=(^2%OH)2CLF%O
MR7>50\9?BI[>T9]Q&8?XAM7%Z'.V)OMI=/NI& W)5ZPP36RN]61 ?9L&5$KR
M(TZX@*=6"G>M9/#U"<LA)'V'IXVO2_PS5^V#>^@8.[0:SM.XRY&Q;_:PK*C[
M+D:>%BD6*IT;2VH3<!M6;WT9#"TE.W "Y[KBS'@ KW1@%Y@Z<)@N6@ 5(ZB?
MG+WY0THI4"M0?"6R\(&8?'/XY 0:N,V@@8<3:.!' 0WTZ.YO!D=PW4:7("#G
M62,-08C$A^+"5DP9X=?IG=>;_2,:%'*2X1<UE^;  Z,2)LK<8YQV<12:(&55
M<\U% 8A6TS2A6W75!@UWI;=6[8A27) MXQCMK'G'UY4OJ&]5%K3MM)W=+X',
M@4YIUK%DEV$F_<^U4&UWBYQR!2J$H-Z;TIK$5 ,./' 94<</^@I7][J@4H98
M2]3!"SI\AIL3NGZ.3_7$1N* 7S:Y.:.[.>NQW)Q7#.T\PU 765Z?0=F0%S48
MHBGV6<FDFY'^Q#9DC;R/!(5ED</4XGSVV%HG@"CU!TJY2QU=,2KH2^NF9NS-
MBGKO.&C_&5,2S^48VX^S< *;$17*OTRM$6Q>NA84JMJ>X+$Y;>>4@-(GBB2'
M(9JC<E(C6TMR8=3;>.D)%H+F*U71SU+*8(=>+:^"O$U9I%124N\Z6^\Y7*K$
MC\/ZW'R#> T<L(<UIJ!; 4(])6FG;QZFNG7P)Z0Q;KH1CJP;+49/"3JZ>GZI
M<!<6Q32;)[.CTU^&>EI-TFYL:??/L:3=B[QJ2CP,UY-R'%=816G.32CU:29
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MW!)W0RAY)?QJW1[2MR:H<G"Y3.B(%"5C$'J#%BD>/XT7<ZHD5(."KH<]%^'
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M_>Z=<BY7QGCT28H]/ITAF['#PBK\8=X:6OLUXITWH15IN@T6]-+4X/F2$CQ
MTM!H7:V(<#E$E42\RK%A[(.I\$9;B]AI,^+.2MAQ.(:S=>>[HZ8>,T2'AMH
MYDV=7MR"1*HN-%U@I&B6%;TTI^E1!K8YJDR6"-E:Y4D.6O9UDGHL;AL9(/G/
MEJ[-'5<O*^A.7=@,83F_[FMCIL)K/5\2%KL\GA(6M@%+=^6(9[NWQI2NB14&
MMF!=%[*8X8511EJ1-Z9P51>U*H(,"<XC*<*U#TR9V]G8';.R^$@-=Z(L*2<M
M.;J6O#^NECR+\=U,9H;V$871@O<@].J]=*7#,S\WM/),4F.YWBE2C"\XTN:?
M>;.::4?#*^5^1&.5VH .$;J4DI48-H#1A_)#G*(4R,F\EL[:$G7T.DNVFR+
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M,BX7(L@T^!XP)4#WK]&HQ&/K^JE,TP?!B5]H3166Q2$"MJ;$F\!0].M[S2:
M"Z5@1 B%[Z<$5MUP!"V8:)4F@&J6 K=!E(7>-0 QW?Y"B.^GRUN>"O9A(7A#
M+PK#FFYIEB21DQW:/G>-[C>B6HA>$;3G62383F-G>_@R3S$:<J&'L5ED34WS
MFQ2,;:/& A_T<O4U"YPKO]D?7W1%A0T(&S87&9$7+!@*EN*Q=19!O'@ ;@MI
M/U$ -R?CWHRUN,5Y]^6*51D;X1P*,Q,B7E&7W-U3,XRZ*SM:8L?'/8OY4*2!
MED.HZG&X=-%#EML[%9OW-]&Z!%(2&6.DQ&:^&HEKJ!-#=S(-+:3$9980C7!/
M<[=D5H[](K@ UN5SZQ6A)S041X]@J,10O2L4.%KMC></A_#46 2\1?6>86G!
M@PDY'.RC(3ZR0!*H5(&!W* @=QU)M-QVZ"<H[%TDMHCPAH:7$N*QP"D&84"M
MRE"8H%,ZXLY_4#7-(%L+ BTTR3>_N R6)N'35$QA3AQR*U+91)0Q7.>FD_;0
MF01\RL*QTPVI@D")-$6;0BKQ!%R2H-TV-H=$S-&C,O */FBQ8&$?2D20^HD4
MJ@]%I&85EC<:/$TAU45H+.(,88XQD:SAV)NG0!(WF1:>$7B&WS$:$6GF^9R%
MG;!_.)7&. =EUI"%']WSP-L(E92>)A\NG?P52[DH>#T"Q)<'2##T#^!1X[0F
M?ZZK6/0]?4ZR(=*>FA=,@>SN J%AY@R$6G]:M %-URAC"^"%@/Z5T#=8#NZB
M 70KJ>5:&U.#LKO>&*T^-L.TN\@E&""06OR12>SHA TW27  QR3K!I(NU*C"
MWM@)Y $.1!%2,W3>4P['ZG29W\64YD6'D<;649B^UL!9Q>S3L3+ :R@2@IW-
MN"OB)EK1)H07]]UH;AWJVW)! MQ8DXB7R&(D=&1M]@5J1J^GAA0@&)5'2"PJ
MU5O%=4C3#R62WJ@-'U&;OOXL];L$;)%'R6:S1PY=T^NBU;8T7D4'&X,\C*LD
MZQ7RPI&YLZ_>:N0*O0,P-&VZ"E1ZS&?Y;<O6UI)\4W&_ GKXKG>\436WY8KC
M8\5 @\)ER<YRG[#F>]L:6&J6>)XM8@;N@]'X,)O(P+<&R[;"/F670*K ;OA5
M7 ?"$]URE[&,U]06+6Q"+#=ZOB0E<PK-,^W:$"%;/48942-#5Y91"&SXTV7?
MNYDP58HUN*D<RLBG=T@ =FQ@JXI!/8OI[= M*P4\2RU^6)Q-J>TAN<YX7!6-
M65D0PJVJME)0KH.-D:JVI;0.$CJ0J4OZK]*#"L_2JTM=?""(APL2EUN#U<+[
MW8CA#!4VCR[:GF6-5#%RUN83!JAGR8-/N+X#/BSGVU) O8D%)NHV<L8ZQ#^
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M#U!+ 0(4 Q0    ( /.!1U'XV1,"I@,  *T,   1              "  0
M  !G;'EC+3(P,C Q,# W+GAS9%!+ 0(4 Q0    ( /.!1U$O;Z<IC@4  -<\
M   5              "  =4#  !G;'EC+3(P,C Q,# W7VQA8BYX;6Q02P$"
M% ,4    " #S@4=1@F8_'8X$  !+*0  %0              @ &6"0  9VQY
M8RTR,#(P,3 P-U]P<F4N>&UL4$L! A0#%     @ \X%'49AC!.W.&0  7+8
M !0              ( !5PX  &=L>6,M,C R,#$P,#=X.&LN:'1M4$L! A0#
M%     @ \X%'43;BG!RM?0  <Z\# !<              ( !5R@  &=L>6,M
M,C R,#$P,#=X97@Q9#$N:'1M4$L! A0#%     @ \X%'45!%(9#P"@  ^S$
M !<              ( !.:8  &=L>6,M,C R,#$P,#=X97@U9#$N:'1M4$L%
3!@     &  8 D0$  %ZQ      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
